var title_f23_50_24352="Noncontact map focal AF";
var content_f23_50_24352=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Noncontact endocardial activation map of focal atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The noncontact endocardial activation map of the half-open left atrium shows that the initial depolarization from an ectopic focus spreads centrifugally from the ostium of the right upper pulmonary vein (RUP), indicated by the white-blue color.",
"    <div class=\"footnotes\">",
"     LUP: left upper pulmonary vein.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Schneider MA, Ndrepepa G, Zrenner B, et al. Noncontact mapping-guided catheter ablation of atrial fibrillation associated with left atrial ectopy. J Cardiovascular Electrophysiol 2000; 11:475. Copyright &copy; 2000 Futura Publishing Company, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_50_24352=[""].join("\n");
var outline_f23_50_24352=null;
var title_f23_50_24353="Thoracoscopic surgery PI";
var content_f23_50_24353=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F54182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F54182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Thoracoscopic surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 656px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thoracoscopic surgery can be used to remove pieces of lung or to do certain types of heart surgery. In this example, a piece of lung is about to be removed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_50_24353=[""].join("\n");
var outline_f23_50_24353=null;
var title_f23_50_24354="Camphor and phenol: Drug information";
var content_f23_50_24354=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"18\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Camphor and phenol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/52/36675?source=see_link\">",
"    see \"Camphor and phenol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Campho-Phenique&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F144897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F144892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of pain/itching: Apply 1-3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F144893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Campho-Phenique&reg;: Camphor 10.8% and phenol 4.7% (7 g, 14 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical: Camphor 10.8% and phenol 4.7% (45 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Campho-Phenique&reg;: Camphor 10.8% and phenol 4.7% (22.5 mL, 45 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Liquid",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F144887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of pain and itching associated with minor burns, sunburn, minor cuts, insect bites, minor skin irritation; temporary relief of pain from cold sores",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F144889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to camphor, phenol, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F144881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &bull; Pediatrics: The American Academy of Pediatrics suggests that camphor be avoided in pediatric patients because of its lack of efficacy and the well-documented toxicity that may occur with use (AAP, 1994). Although toxicity most often results from oral ingestion of topical or inhalation products, combined dermal and inhalation exposure has resulted in toxicity (Love, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only; do not cover affected area with bandage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self-medication (OTC use), do not use on deep puncture wounds, animal bites, serious burns, or for &gt;7 days.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F144884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14276562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following exposure to large concentrations (eg, oral ingestion observed with poisonings), camphor crosses the placenta and is toxic to the fetus (Rabl, 1997).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Campho-Phenique External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10.8-4.7% (6.5 g): $3.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Campho-Phenique External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10.8-4.7% (22.5 mL): $3.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Camphor-Phenol External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10.8-4.7% (45 mL): $4.75",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Camphor Revisited: Focus on Toxicity,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1994, 94(1):127-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/50/24354/abstract-text/8008522/pubmed\" id=\"8008522\" target=\"_blank\">",
"        8008522",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Love JN, Sammon M, and Smereck J, &ldquo;Are One Or Two Dangerous? Camphor Exposure In Toddlers,&rdquo;",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 2004, 27(1):49-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/50/24354/abstract-text/15219304/pubmed\" id=\"15219304\" target=\"_blank\">",
"        15219304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabl W, Katzgraber F, and Steinlechner M, \"Camphor Ingestion for Abortion (Case Report),\"",
"      <i>",
"       Forensic Sci Int",
"      </i>",
"      , 1997, 89(1-2):137-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/50/24354/abstract-text/9306672/pubmed\" id=\"9306672\" target=\"_blank\">",
"        9306672",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8835 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-EFB8DDA1F5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_50_24354=[""].join("\n");
var outline_f23_50_24354=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144891\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144897\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144892\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144893\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144886\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144878\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144887\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144889\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144881\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298948\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218846\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144884\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14276562\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323039\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8835\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8835|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/52/36675?source=related_link\">",
"      Camphor and phenol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_50_24355="Takayasu arteritis aneurysm 2";
var content_f23_50_24355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fusiform aneurysm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Enlargement of the contrast filled descending thoracic aneurysm has occurred despite treatment with glucocorticoids.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sueyoshi E, Sakamoto I, Hayashi K. Aortic aneurysms in patients with Takayasu's arteritis: CT evaluation. Am J Roentgenology 2000; 175:1727. Copyright &copy; 2000 American Roentgen Ray Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_50_24355=[""].join("\n");
var outline_f23_50_24355=null;
var title_f23_50_24356="Isosorbide dinitrate: Patient drug information";
var content_f23_50_24356=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Isosorbide dinitrate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     see \"Isosorbide dinitrate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dilatrate&reg;-SR;",
"     </li>",
"     <li>",
"      IsoDitrate&reg; ER;",
"     </li>",
"     <li>",
"      Isordil&reg; Titradose&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F184984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      ISDN;",
"     </li>",
"     <li>",
"      Isosorbide;",
"     </li>",
"     <li>",
"      Novo-Sorbide;",
"     </li>",
"     <li>",
"      PMS-Isosorbide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691499",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat chest pain or pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to isosorbide dinitrate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache. Most of the time it gets better after taking this drug for a week.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698621",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure lasting more than 15 minutes.",
"       <b>",
"        Get emergency medical care right away.",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695688",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sublingual tablet: Place under your tongue and let melt.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10775 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-7B5B02C4AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_50_24356=[""].join("\n");
var outline_f23_50_24356=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184983\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184984\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020141\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020143\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020142\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020147\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020148\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020150\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020145\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020146\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020151\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020152\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=related_link\">",
"      Isosorbide dinitrate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_50_24357="RA hand 1";
var content_f23_50_24357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F57439%7ERHEUM%2F66140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F57439%7ERHEUM%2F66140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Synovial thickening of the metacarpophalangeal joint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral swelling of the MCP joints is evident in this patient with rheumatoid arthritis. Note also the mild swan neck deformities present in several fingers, particularly the left middle and fifth fingers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Patrick J Venables, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Swelling of the metacarpophalangeal joints of the right hand in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 211px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Swelling of the MCP joints, moderate MCP flexion, and swan neck deformities are evident in this patient with rheumatoid arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Patrick J Venables, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_50_24357=[""].join("\n");
var outline_f23_50_24357=null;
var title_f23_50_24358="Insulin aspart: Pediatric drug information";
var content_f23_50_24358=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Insulin aspart: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10920?source=see_link\">",
"    see \"Insulin aspart: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/14/229?source=see_link\">",
"    see \"Insulin aspart: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2104823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      NovoLOG&reg;;",
"     </li>",
"     <li>",
"      NovoLOG&reg; FlexPen&reg;;",
"     </li>",
"     <li>",
"      NovoLOG&reg; Penfill&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2104824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      NovoRapid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2984472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiabetic Agent, Parenteral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Insulin, Rapid-Acting",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F991011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10920?source=see_link\">",
"      see \"Insulin aspart: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin aspart is a rapid-acting insulin analog which is normally administered SubQ as a premeal component of the insulin regimen or as a continuous SubQ infusion and should be used with intermediate- or long-acting insulin. When compared to insulin regular, insulin aspart has a more rapid onset and shorter duration of activity. In carefully controlled clinical settings with close medical supervision and monitoring of blood glucose and potassium, insulin aspart may also be administered I.V. Insulin requirements vary dramatically between patients and dictate frequent monitoring and close medical supervision. See Insulin Regular for additional information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General insulin dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Type 1 diabetes mellitus:",
"     </b>",
"     Children, Adolescents, and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Multiple daily doses or continuous subcutaneous infusions guided by blood glucose monitoring are the standard of diabetes care. Combinations of insulin formulations are commonly used.  The daily doses presented below are expressed as the",
"     <b>",
"      total units/kg/day of all insulin formulations combined",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Initial total insulin dose:",
"     </b>",
"     SubQ: 0.2-0.6 units/kg/day in divided doses. Conservative initial doses of 0.2-0.4 units/kg/day are often recommended to avoid the potential for hypoglycemia. A rapidly acting insulin may be the only insulin formulation used initially.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Usual maintenance range:",
"     </b>",
"     SubQ: 0.5-1 unit/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: May require &le;1.2 units/kg/day during growth spurts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Nonobese: 0.4-0.6 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Obese: 0.8-1.2 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Adjustment of dose:",
"     </b>",
"     Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Continuous SubQ insulin infusion (insulin pump):",
"     </b>",
"     A combination of a \"basal\" continuous insulin infusion rate  with preprogrammed, premeal bolus doses which are patient controlled. When converting from multiple daily SubQ doses of maintenance insulin, it is advisable to reduce the basal rate to less than the equivalent of the total daily units of longer acting insulin (eg, NPH); divide the total number of units by 24 to get the basal rate in units/hour. Do not include the total units of regular insulin or other rapid-acting insulin formulations in this calculation. The same premeal regular insulin dosage may be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Type 2 diabetes mellitus:",
"     </b>",
"     Augmentation therapy (patients for which diet, exercise, weight reduction, and oral hypoglycemic agents have not been adequate): Adults: SubQ: Initial dosage of 0.2 units/kg/day or 10 units/day of an intermediate-acting (eg, NPH) or long-acting insulin administered at bedtime has been recommended. As an alternative, regular insulin or rapid-acting insulin formulations administered before meals have also been used. Dosage must be carefully adjusted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Insulin requirements are reduced due to changes in insulin clearance or metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2104880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NovoLOG&reg;: 100 units/mL (10 mL) [vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NovoLOG&reg; FlexPen&reg;: 100 units/mL (3 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NovoLOG&reg; Penfill&reg;: 100 units/mL (3 mL) [cartridge]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2142861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2529650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SubQ: Administration is usually made into the subcutaneous fat of the thighs, arms, buttocks, or abdomen, with sites rotated; cold injections should be avoided. May be mixed in the same syringe with NPH insulin. When mixing insulin aspart with NPH insulin, aspart should be drawn into the syringe first. Administer immediately before meals (within 5-10 minutes of the start of a meal). Can be infused SubQ by external insulin pump; however, when used in an external pump, it is not recommended to be diluted with other insulin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Insulin aspart may be administered I.V. in selected clinical situations to control hyperglycemia. Appropriate medical supervision is required. May be diluted to a concentration between 0.05 and 1 unit/mL with NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, or D",
"     <sub>",
"      10",
"     </sub>",
"     W",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2104852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, and NS.",
"     <b>",
"      Note:",
"     </b>",
"     Insulin Diluting Medium for NovoLog&reg; is available from the manufacturer for SubQ administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Insulin NPH.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Insulin detemir, insulin glargine, insulin glulisine, insulin lispro, insulin regular.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2984476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Store unopened container in refrigerator; do not freeze; protect from heat and light. Once opened (in use) vials may be stored in refrigerator or at room temperature for up to 28 days. Cartridges that are in use should be stored at room temperature and used within 28 days; do not refrigerate. Insulin in reservoir should be replaced every 48 hours. Discard if exposed to temperatures &ge;37&deg;C (98.6&deg;F). May be mixed in the same syringe with NPH insulin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F991010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 1 diabetes mellitus (insulin dependent, IDDM); type 2 diabetes mellitus (noninsulin dependent, NIDDM) to control hyperglycemia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2105009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       NovoLOG&reg; may be confused with HumaLOG&reg;, HumuLIN&reg; R, Nimbex&reg;, NovoLIN&reg; N, NovoLIN&reg; R, NovoLOG&reg; Mix 70/30",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"       <b>",
"        <i>",
"         Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.",
"        </i>",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F2104842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Primarily symptoms of hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Pallor, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, hypothermia, loss of consciousness, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Redness, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Hunger, nausea, numbness of mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Atrophy or hypertrophy of SubQ fat tissue; edema, itching, pain or warmth at injection site; stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Transient presbyopia or blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, local and/or systemic hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2984473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity insulin aspart or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2984474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use with caution and adjust dosage in patients with renal impairment; use with caution and monitor closely in patient with hepatic impairment. While regular insulin is the preferred formulation for I.V. administration, both insulin aspart and insulin glulisine have been approved for I.V. use in selected clinical situations with close medical supervision and monitoring of serum potassium.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2529647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypoglycemia is the most common adverse effect of insulin. The timing of hypoglycemia differs among various insulin formulations. Any change of insulin should be made cautiously; changing manufacturers, type, and/or method of manufacture may result in the need for a change of dosage. Hypoglycemia may result from increased work or exercise without eating.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8101785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2104847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Insulin may enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Insulin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Insulin may enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2984475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use caution with chromium, garlic, gymnema (may increase hypoglycemia).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2104831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2104832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is &gt;1% above the normal range.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28-32 weeks of gestation. Following delivery, insulin requirements decrease rapidly. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the fetus and the mother. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy. Insulin aspart has been demonstrated to be as safe and effective as regular human insulin when used during pregnancy and may have advantages over regular insulin during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2984480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urine sugar and acetone, serum glucose, electrolytes, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     , lipid profile; when used intravenously, close monitoring of serum glucose and potassium are required to avoid hypoglycemia and/or hypokalemia",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2984501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucose, fasting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 30-90 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 70-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommendations for glycemic control with type 1 diabetes:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;6 years: &le;8.5% and &ge;7.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-12 years: &lt;8%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     13-19 years: &lt;7.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: &lt;7%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plasma glucose*:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Preprandial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;6 years: 90-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-12 years: 90-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     13 years to Adults: 90-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bedtime and overnight:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;6 years: 110-200 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-12 years: 100-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     13-19 years: 90-150 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peak postprandial** : Adults: &lt;180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     *Plasma glucose concentrations are generally 10% to 15% higher than those in whole blood",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     **Peak postprandial plasma glucose is measured 1-2 hours after a meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Criteria for diagnosis of DKA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum glucose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: &gt;200 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: &gt;250 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Arterial pH:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: &lt;7.3",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: &lt;7-7.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bicarbonate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: &lt;15 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: &lt;10-15 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate ketonuria or ketonemia",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2984477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Insulin facilitates entry of glucose into muscle, adipose, and other tissues via hexose transporters, including GLUT4. Insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Target organs for insulin include the liver, skeletal muscle, and adipose tissue. Within the liver, insulin stimulates hepatic glycogen synthesis through the activation of the enzymes hexokinase, phosphofructokinase, and glycogen synthase as well as the inhibition of glucose-6 phosphatase. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes. Insulin also directly inhibits the hydrolysis of triglycerides.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either",
"     <i>",
"      E. coli",
"     </i>",
"     or",
"     <i>",
"      Saccharomyces cerevisiae",
"     </i>",
"     . Insulins are categorized based on promptness and duration of effect, including rapid-, short-, intermediate-, and long-acting insulins. Insulin aspart is a \"rapid-acting\" insulin analog.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F2984478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Onset and duration of hypoglycemic effects depend upon the route of administration (adsorption and onset of action are more rapid after deeper I.M. injections than after SubQ), site of injection (onset and duration are progressively slower with SubQ injection into the abdomen, arm, buttock, or thigh respectively), volume and concentration of injection, and the preparation administered; local heat and massage also increase the rate of absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 0.17-0.33 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 3-5 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2984479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 0% to 9%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 81 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 40-50 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Adults: 1.22 L/hour/kg",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F2984502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/14/229?source=see_link\">",
"      see \"Insulin aspart: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new medication during therapy unless approved by healthcare provider. This medication is used to control diabetes; it is not a cure. It is imperative to follow other components of prescribed treatment (eg, diet and exercise regimen). Take exactly as directed. Do not change dose or discontinue unless advised by healthcare provider. With insulin aspart (NovoLog&reg;), you must start eating within 5-10 minutes after injection. If you experience hypoglycemic reaction, contact healthcare provider immediately. Always carry quick source of sugar with you. Monitor glucose levels as directed by healthcare provider. Report adverse side effects, including chest pain or palpitations; persistent fatigue, confusion, headache; skin rash or redness; numbness of mouth, lips, or tongue; muscle weakness or tremors; vision changes; respiratory difficulty; or nausea, vomiting, or flu-like symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F14455404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Division of daily insulin requirement (\"conventional therapy\"):",
"     </b>",
"     Generally, 50% to 75% of the daily insulin dose is given as an intermediate- or long-acting form of insulin (in 1-2 daily injections). The remaining portion of the 24-hour insulin requirement is divided and administered as either regular insulin or a rapid-acting form (eg, insulin aspart) of insulin at the same time before breakfast and dinner.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Division of daily insulin requirement (\"intensive therapy\"):",
"     </b>",
"     Basal insulin delivery with 1 or 2 doses of intermediate- or long-acting insulin formulations superimposed with doses of rapid- or very rapid-acting insulin (eg, insulin aspart) formulations 3 or more times daily.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13379 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_50_24358=[""].join("\n");
var outline_f23_50_24358=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104823\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104824\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984472\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F991011\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104880\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2142861\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2529650\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104852\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984476\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F991010\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2105009\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104842\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984473\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984474\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2529647\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8101785\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104847\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984475\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104831\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104832\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984480\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984501\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984477\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984478\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984479\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984502\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14455404\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13379\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13379|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10920?source=related_link\">",
"      Insulin aspart: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/14/229?source=related_link\">",
"      Insulin aspart: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_50_24359="HIV-associated eosinophilic folliculitis";
var content_f23_50_24359=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   HIV-associated eosinophilic folliculitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/50/24359/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/50/24359/contributors\">",
"     Priya Rajendran, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/50/24359/contributors\">",
"     Whitney A High, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/50/24359/contributors\">",
"     Toby Maurer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/50/24359/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/50/24359/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/50/24359/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/50/24359/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/50/24359/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilic folliculitis (EF) is a pruritic skin eruption consisting of follicular papules or pustules, predominantly located on the scalp, face, neck, and upper chest.",
"   </p>",
"   <p>",
"    EF is a relatively common skin eruption in patients with advanced HIV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A clinically distinct form of EF (Ofuji's disease) has also been described in otherwise healthy individuals, particularly in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/3\">",
"     3",
"    </a>",
"    ]. Other rare types of non-HIV-associated EF include infantile EF and EF associated with bone marrow transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Non-HIV-associated EF has also been described as a rare side effect of medication, including chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the presentation and management of HIV-associated EF. Bacterial folliculitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22387?source=see_link\">",
"     \"Folliculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-associated EF most commonly occurs in patients with late-stage disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    low CD4 counts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/1\">",
"     1",
"    </a>",
"    ]. EF has been reported in HIV-infected men, women, and children [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The prevalence is uncertain, although one series of HIV patients reported folliculitis in 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/10\">",
"     10",
"    </a>",
"    ]. In our experience, since the advent of highly active antiretroviral therapy, EF has become less common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of EF is unknown. Clinical characteristics of EF suggest that it may be an inflammatory disease related to immune dysregulation, perhaps in association with an underlying infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Etiologic hypotheses include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Demodex mites &ndash;",
"      </strong>",
"      It has been suggested that Demodex may play a role in the pathogenesis of EF [",
"      <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. However, a case series of 18 patients found Demodex in only four, and in those four cases the mite was not associated with a surrounding inflammatory response, suggesting that it was not the cause of the folliculitis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Pityrosporum yeast",
"      </strong>",
"      &ndash; It has been hypothesized that HIV-infected persons with immunodysregulation could develop a hypersensitivity reaction to commensal follicular Pityrosporum organisms; however, histopathologic examination in 70 cases demonstrated appreciable yeast forms in just one case [",
"      <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Bacteria &ndash;",
"      </strong>",
"      Responses to antibiotics such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      has raised the possibility of a bacterial infection; however, bacteria are not consistently found in patients who respond to antibiotic treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/17\">",
"       17",
"      </a>",
"      ]. Additionally, most patients do not get prolonged benefits from antibiotic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Autoimmunity &ndash;",
"      </strong>",
"      Based on the known association of autoimmune disease with HIV infection, and the sebaceous distribution of lesions in EF, it has been suggested that EF might be an autoimmune reaction to sebocytes or a constituent of sebum [",
"      <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-associated EF was first described in patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/18\">",
"     18",
"    </a>",
"    ], and it typically occurs in late-stage disease. Patients typically have CD4 cell counts below 250",
"    <span class=\"nowrap\">",
"     cells/&micro;L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/1\">",
"     1",
"    </a>",
"    ], with a mean CD4 count of 64",
"    <span class=\"nowrap\">",
"     cells/&micro;L",
"    </span>",
"    in a series of 18 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/15\">",
"     15",
"    </a>",
"    ], and a mean CD4 count of 116",
"    <span class=\"nowrap\">",
"     cells/&micro;L",
"    </span>",
"    in a series of 57 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-associated EF is characterized by recurrent, pruritic crops of discrete, erythematous, urticarial follicular papules and rare pustules, with a diameter of 3 to 5 mm (",
"    <a class=\"graphic graphic_picture graphicRef87125 graphicRef54404 \" href=\"UTD.htm?34/55/35703\">",
"     picture 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The most common areas of involvement are the scalp, face, neck, and upper trunk; all are areas with a high concentration of sebaceous glands. In a series of 13 patients, all 13 had lesions on the trunk, 11 had lesions on the head and neck, and 8 had lesions on the proximal aspects of their extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/1\">",
"     1",
"    </a>",
"    ]. Two main patterns of distribution were identified: lesions concentrated on the trunk with a few on the face; lesions predominantly on the forehead and beard areas with limited truncal involvement. Facial involvement may be particularly common in women with EF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intense, intractable pruritus is typical [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/15\">",
"     15",
"    </a>",
"    ]. True pustules are rarely observed, as the lesions are typically so pruritic that the lesions are excoriated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/1,21\">",
"     1,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of HIV-associated EF includes acne, bacterial folliculitis, Pityrosporum folliculitis, steroid folliculitis, follicular impetigo, pustular psoriasis, atopic dermatitis, scabies, pruritic papular eruption, papular urticaria, and drug eruption. In one prospective study of 51 HIV-positive patients with pruritic folliculitis, histopathologic examination revealed evidence for EF in 23 (45 percent), bacterial folliculitis in 21 (41 percent), Pityrosporum folliculitis in 5 (10 percent), and Demodex folliculitis in 2 (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28423?source=see_link\">",
"     \"Approach to the patient with pustular skin lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pruritic papular eruption (PPE) is an intensely pruritic skin rash seen commonly in people infected with HIV in sub-Saharan Africa. Although the etiology is uncertain, there is some evidence that it involves an exaggerated reaction to arthropod bites (",
"    <a class=\"graphic graphic_picture graphicRef82671 \" href=\"UTD.htm?41/11/42175\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pustules in EF are usually smaller than those in bacterial folliculitis. Although the diagnosis can be strongly suspected clinically in patients with a low CD4 count and a pruritic follicular rash in a typical distribution, skin biopsy is needed to confirm the diagnosis. The main distinction is between EF and infective folliculitis. In a series of 23 HIV-infected patients with itchy folliculitis, 18 (78 percent) had EF and 5 (22 percent) had infective folliculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22387?source=see_link\">",
"     \"Folliculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peripheral eosinophilia and elevated serum IgE are seen in about 25 to 50 percent of patients with HIV-associated EF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/15,21\">",
"     15,21",
"    </a>",
"    ]. Because of this low sensitivity, these tests are not routinely performed for diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common histopathologic findings of EF include perifollicular infiltrates of lymphocytes and eosinophils along with spongiosis of follicular epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/16\">",
"     16",
"    </a>",
"    ]. The lymphocytic and eosinophilic infiltrate is often focused at the level of the isthmus, where the sebaceous gland and duct enter the follicle [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Lysis of sebaceous ducts can be seen.",
"   </p>",
"   <p>",
"    Histological findings may be useful for differentiating EF from other disorders. In a series that compared 52 specimens from 50 patients with HIV-associated EF with 6 specimens of suppurative folliculitis in patients with HIV infection, biopsies of EF were distinct from those of suppurative folliculitis in that suppurative folliculitis demonstrated a predominance of neutrophils and macrophages within the infiltrate, microorganisms were easily identified, and there was often rupture of the involved follicle (",
"    <a class=\"graphic graphic_picture graphicRef78005 graphicRef67192 \" href=\"UTD.htm?22/7/22649\">",
"     picture 3A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the results of a small retrospective study suggest that histological features and immunohistochemical stains may be of value for distinguishing EF from PPE [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients with EF demonstrated more intense inflammatory infiltrates, higher counts of tissue mast cells, and higher expression levels of CD15, CD4, and CD7. Additional studies are necessary to confirm these findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike Ofuji's disease (EF in otherwise healthy individuals), HIV-associated EF does not normally respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/11\">",
"     11",
"    </a>",
"    ]. Various treatments have been tried for HIV-associated EF, but there are no controlled trials comparing treatments with each other or with placebo. As discussed below, patients who respond to antiretroviral therapy generally show improvement or resolution of their EF. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Antiretroviral therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The treatments discussed below are frequently used in combination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Topical corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potent topical corticosteroids (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ) are a common first-line treatment option. They can decrease pruritus, but they do not suppress the development of new lesions and may not fully control symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/11,25\">",
"     11,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of H1 and H2 blocking agents, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    , are also used as first-line treatments to control pruritus. A single case report of a patient successfully treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    led the authors to hypothesize that antieosinophil properties possessed by cetirizine may result in increased efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/26\">",
"     26",
"    </a>",
"    ]. In our experience, the efficacy of systemic antihistamines in patients with HIV-associated EF has been disappointing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Itraconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    may be of benefit in patients with HIV-associated EF. In an open study, 28 HIV-positive men were treated with itraconazole 100 to 400 mg daily [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/27\">",
"     27",
"    </a>",
"    ]. Complete response was seen in 17 patients and partial improvement in 4 patients. All patients who improved responded within two weeks.",
"   </p>",
"   <p>",
"    A patient who was switched to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    had a relapse of EF, and two other patients received fluconazole without improvement, one of whom improved with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/27\">",
"     27",
"    </a>",
"    ]. This differential response to fluconazole raises the possibility that the effect of itraconazole is due to an antiinflammatory effect rather than an antimycotic effect. Patients treated with itraconazole should have liver function tests monitored, and drug-drug interactions should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Topical calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    have been reported to have some benefit in patients with Ofuji's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. A case series reported rapid improvement in eight patients with HIV-associated EF who were treated with once daily topical tacrolimus 0.1 percent; three of the patients had developed EF in the setting of recently initiating ART [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/31\">",
"     31",
"    </a>",
"    ]. The authors reported that they have not had similar success treating EF with either tacrolimus 0.03 percent or with pimecrolimus.",
"   </p>",
"   <p>",
"    Concerns have been raised about the safety of topical calcineurin inhibitors, with a recommendation by the United States FDA to avoid their use in patients with compromised immune systems (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Topical calcineurin inhibitors'",
"    </a>",
"    ). We suggest not treating EF with topical calcineurin inhibitors until further information on safety and efficacy is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Topical permethrin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     permethrin",
"    </a>",
"    5 percent applied daily was effective in six patients with treatment-resistant HIV-associated EF who were found to have increased numbers of Demodex mites on skin biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/14\">",
"     14",
"    </a>",
"    ]. Lesions recurred when therapy was discontinued. It is uncertain whether the effect of permethrin was due to reducing numbers of Demodex mites or to other antiinflammatory properties. We sometimes utilize permethrin in combination with systemic therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ); however, the efficacy of such combination therapy is not established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Retinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data supporting the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    in HIV-associated EF are limited to case reports and small, uncontrolled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/22,32,33\">",
"     22,32,33",
"    </a>",
"    ]. Isotretinoin is most commonly administered in doses of 0.5 to 1.2",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    and typical treatment durations range from a few weeks to a few months.",
"   </p>",
"   <p>",
"    The risk for relapse after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    therapy may be high. In a pilot study in which seven patients were treated with courses of isotretinoin ranging from 2 to 17 weeks, relapse occurred within nine months of the discontinuation of therapy in all patients, including three patients who were given multiple courses of therapy secondary to rapid initial relapses [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     Isotretinoin",
"    </a>",
"    is a drug that can virtually halt sebum production, and proponents of an autoimmune reaction to sebum as the etiology of HIV-associated EF suggest that this may be the explanation for its efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/15\">",
"     15",
"    </a>",
"    ]. The drug is teratogenic and also can induce a variety of cutaneous and systemic adverse effects. Due to the limited data in support of the efficacy of isotretinoin, the possibility of relapse upon the cessation of therapy, and the potential adverse effects of this drug, the use of isotretinoin for HIV-associated EF should be considered carefully. In the United States, isotretinoin must be prescribed through the",
"    <a class=\"external\" href=\"https://www.ipledgeprogram.com/\">",
"     iPLEDGE program",
"    </a>",
"    , an internet-based registry that was created to reduce the incidence of fetal exposure to isotretinoin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22184?source=see_link&amp;anchor=H7#H7\">",
"     \"Oral isotretinoin therapy for acne vulgaris\", section on 'Isotretinoin safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports and case series have reported that phototherapy with ultraviolet B (UVB) is effective for HIV-associated EF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. As an example, a series of six patients with EF who had not responded to other therapies all reported a decrease in pruritus after multiple treatments with UVB therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with a systemic psoralen-based photosensitizer plus ultraviolet A (PUVA) has also been used successfully to treat HIV-associated EF. The increased toxicity profile of PUVA makes UVB preferable initially [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    UV phototherapy is known to suppress T-cell mediated processes and also to induce activation and replication of HIV, leading some to question its safety in HIV-infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/38\">",
"     38",
"    </a>",
"    ]. However, most evidence suggests such treatment is not associated with clinical deterioration and that it can be safely used in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Metronidazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a series of five patients with severe HIV-associated EF unresponsive to other therapies,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    250 mg three times daily for three to four weeks resulted in complete clearing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/17\">",
"     17",
"    </a>",
"    ]. Two patients had recurrences within a few months and responded to retreatment with oral metronidazole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dapsone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    has demonstrated variable success in treating Ofuji's disease and has been used in HIV-associated EF as well [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/11,41,42\">",
"     11,41,42",
"    </a>",
"    ]. Dapsone suppresses the activity of myeloperoxidase within neutrophils, and there is evidence to suggest it may suppress eosinophil peroxidase within eosinophils as well [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/43\">",
"     43",
"    </a>",
"    ]. The typical dose is 50 to 100 mg, once or twice a day [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Oral glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral glucocorticoids are occasionally used to treat HIV-associated EF. A typical initial dosage is approximately 1",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/11,44\">",
"     11,44",
"    </a>",
"    ]. The decision to use systemic glucocorticoids must take into account the typical adverse effects of oral glucocorticoids, particularly in immunocompromised patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient treated for Pneumocystis jirovecii pneumonia (PCP) with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    reportedly showed improvement in his EF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/33\">",
"     33",
"    </a>",
"    ]. Other treatments that have been reported to show benefit in Ofuji's disease, though not necessarily in HIV-associated EF, include oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    and clofazimine [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not formally studied in clinical trials, there is widespread recognition that HIV-associated EF improves or resolves in most patients treated with antiretroviral therapy (ART). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are case reports of EF flaring during the first two to six months of ART, consistent with immune reconstitution inflammatory syndrome (IRIS) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/19,45\">",
"     19,45",
"    </a>",
"    ]. In a series of 34 cases of EF in patients on ART, 28 (82 percent) occurred within six months of initiating ART [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24359/abstract/19\">",
"     19",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    ). Patients who appear to have a flare of EF as a manifestation of IRIS are typically treated with another therapy for EF for a period of several weeks to months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV-associated EF is a chronic pruritic skin eruption of uncertain etiology associated with low CD4 counts and later stage disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis depends upon clinical suspicion, an appropriate presentation (intensely pruritic follicular lesions generally on the upper trunk, face, neck, or scalp), and histological confirmation via skin biopsy of an unexcoriated lesion. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no controlled trials of therapy for HIV-associated EF. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are treated with ART typically show improvement or resolution of EF, and ART is the primary therapy for EF in such patients. During the initial two to six months of ART, there may be a flare of EF (immune reconstitution inflammatory syndrome). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Antiretroviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a clinical diagnosis of EF who cannot be treated with ART, or who develop a flare early in the course of ART can be treated with high potency topical corticosteroids (or medium potency topical corticosteroids for facial lesions) in combination with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"       doxepin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"       hydroxyzine",
"      </a>",
"      while awaiting histologic confirmation of the diagnosis (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      ). Upon confirmation by biopsy, oral agents (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      ) may be added. Higher doses of itraconazole, oral retinoids,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ultraviolet light therapy can be used if there is inadequate improvement. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/1\">",
"      Rosenthal D, LeBoit PE, Klumpp L, Berger TG. Human immunodeficiency virus-associated eosinophilic folliculitis. A unique dermatosis associated with advanced human immunodeficiency virus infection. Arch Dermatol 1991; 127:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/2\">",
"      Majors MJ, Berger TG, Blauvelt A, et al. HIV-related eosinophilic folliculitis: a panel discussion. Semin Cutan Med Surg 1997; 16:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/3\">",
"      Ofuji S, Ogino A, Horio T, et al. Eosinophilic pustular folliculitis. Acta Derm Venereol 1970; 50:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/4\">",
"      Keida T, Hayashi N, Kawashima M. Eosinophilic pustular folliculitis following autologous peripheral blood stem-cell transplantation. J Dermatol 2004; 31:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/5\">",
"      Fraser SJ, Benton EC, Roddie PH, et al. Eosinophilic folliculitis: an important differential diagnosis after allogeneic bone-marrow transplant. Clin Exp Dermatol 2009; 34:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/6\">",
"      Laing ME, Laing TA, Mulligan NJ, Keane FM. Eosinophilic pustular folliculitis induced by chemotherapy. J Am Acad Dermatol 2006; 54:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/7\">",
"      Basarab T, Russell Jones R. HIV-associated eosinophilic folliculitis: case report and review of the literature. Br J Dermatol 1996; 134:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/8\">",
"      Ramdial PK, Morar N, Dlova NC, Aboobaker J. HIV-associated eosinophilic folliculitis in an infant. Am J Dermatopathol 1999; 21:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/9\">",
"      Hayes BB, Hille RC, Goldberg LJ. Eosinophilic folliculitis in 2 HIV-positive women. Arch Dermatol 2004; 140:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/10\">",
"      Uthayakumar S, Nandwani R, Drinkwater T, et al. The prevalence of skin disease in HIV infection and its relationship to the degree of immunosuppression. Br J Dermatol 1997; 137:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/11\">",
"      Ellis E, Scheinfeld N. Eosinophilic pustular folliculitis: a comprehensive review of treatment options. Am J Clin Dermatol 2004; 5:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/12\">",
"      Magro CM, Crowson AN. Eosinophilic pustular follicular reaction: a paradigm of immune dysregulation. Int J Dermatol 1994; 33:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/13\">",
"      Bodokh I, Lacour JP, Perrin C, et al. Papular eruption in AIDS: role of demodectic mites? Acta Derm Venereol 1994; 74:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/14\">",
"      Blauvelt A, Plott RT, Spooner K, et al. Eosinophilic folliculitis associated with the acquired immunodeficiency syndrome responds well to permethrin. Arch Dermatol 1995; 131:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/15\">",
"      Fearfield LA, Rowe A, Francis N, et al. Itchy folliculitis and human immunodeficiency virus infection: clinicopathological and immunological features, pathogenesis and treatment. Br J Dermatol 1999; 141:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/16\">",
"      McCalmont TH, Altemus D, Maurer T, Berger TG. Eosinophilic folliculitis. The histologic spectrum. Am J Dermatopathol 1995; 17:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/17\">",
"      Smith KJ, Skelton HG, Yeager J, et al. Metronidazole for eosinophilic pustular folliculitis in human immunodeficiency virus type 1-positive patients. Arch Dermatol 1995; 131:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/18\">",
"      Soeprono FF, Schinella RA. Eosinophilic pustular folliculitis in patients with acquired immunodeficiency syndrome. Report of three cases. J Am Acad Dermatol 1986; 14:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/19\">",
"      Rajendran PM, Dolev JC, Heaphy MR Jr, Maurer T. Eosinophilic folliculitis: before and after the introduction of antiretroviral therapy. Arch Dermatol 2005; 141:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/20\">",
"      Parker SR, Parker DC, McCall CO. Eosinophilic folliculitis in HIV-infected women: case series and review. Am J Clin Dermatol 2006; 7:193.",
"     </a>",
"    </li>",
"    <li>",
"     Odom RB, James WD, Berger TG. Andrews' diseases of the skin: Clinical dermatology, WB Saunders Company, Philadelphia 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/22\">",
"      Annam V, Yelikar BR, Inamadar AC, et al. Clinicopathological study of itchy folliculitis in HIV-infected patients. Indian J Dermatol Venereol Leprol 2010; 76:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/23\">",
"      Resneck JS Jr, Van Beek M, Furmanski L, et al. Etiology of pruritic papular eruption with HIV infection in Uganda. JAMA 2004; 292:2614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/24\">",
"      Afonso JP, Tomimori J, Michalany NS, et al. Pruritic papular eruption and eosinophilic folliculitis associated with human immunodeficiency virus (HIV) infection: a histopathological and immunohistochemical comparative study. J Am Acad Dermatol 2012; 67:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/25\">",
"      Grange F, Schoenlaub P, Tortel MC, et al. [AIDS-related eosinophilic folliculitis. Efficacy of high dose topical corticotherapy]. Ann Dermatol Venereol 1996; 123:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/26\">",
"      Harris DW, Ostlere L, Buckley C, et al. Eosinophilic pustular folliculitis in an HIV-positive man: response to cetirizine. Br J Dermatol 1992; 126:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/27\">",
"      Berger TG, Heon V, King C, et al. Itraconazole therapy for human immunodeficiency virus-associated eosinophilic folliculitis. Arch Dermatol 1995; 131:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/28\">",
"      Kawaguchi M, Mitsuhashi Y, Kondo S. Successful treatment of eosinophilic pustular folliculitis with topical tacrolimus. Int J Dermatol 2004; 43:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/29\">",
"      Dale S, Shaw J. Clinical picture. Eosinophilic pustular folliculitis. Lancet 2000; 356:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/30\">",
"      Rho NK, Kim BJ. Eosinophilic pustular folliculitis: successful treatment with topical pimecrolimus. Clin Exp Dermatol 2007; 32:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/31\">",
"      Toutous-Trellu L, Abraham S, Pech&egrave;re M, et al. Topical tacrolimus for effective treatment of eosinophilic folliculitis associated with human immunodeficiency virus infection. Arch Dermatol 2005; 141:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/32\">",
"      Otley CC, Avram MR, Johnson RA. Isotretinoin treatment of human immunodeficiency virus-associated eosinophilic folliculitis. Results of an open, pilot trial. Arch Dermatol 1995; 131:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/33\">",
"      Downs AM, Lear JT, Oxley JD, Kennedy CT. AIDS associated eosinophilic folliculitis which responded to both high dose co-trimoxazole and low dose isotretinoin. Sex Transm Infect 1998; 74:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/34\">",
"      Buchness MR, Lim HW, Hatcher VA, et al. Eosinophilic pustular folliculitis in the acquired immunodeficiency syndrome. Treatment with ultraviolet B phototherapy. N Engl J Med 1988; 318:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/35\">",
"      Porneuf M, Guillot B, Barneon G, Guilhou JJ. Eosinophilic pustular folliculitis responding to UVB therapy. J Am Acad Dermatol 1993; 29:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/36\">",
"      Misago N, Narisawa Y, Matsubara S, Hayashi S. HIV-associated eosinophilic pustular folliculitis: successful treatment of a Japanese patient with UVB phototherapy. J Dermatol 1998; 25:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/37\">",
"      Kuwano Y, Watanabe R, Fujimoto M, et al. Treatment of HIV-associated eosinophilic pustular folliculitis with narrow-band UVB. Int J Dermatol 2006; 45:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/38\">",
"      Adams ML, Houpt KR, Cruz PD Jr. Is phototherapy safe for HIV-infected individuals? Photochem Photobiol 1996; 64:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/39\">",
"      Meola T, Soter NA, Ostreicher R, et al. The safety of UVB phototherapy in patients with HIV infection. J Am Acad Dermatol 1993; 29:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/40\">",
"      Akaraphanth R, Lim HW. HIV, UV and immunosuppression. Photodermatol Photoimmunol Photomed 1999; 15:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/41\">",
"      Steffen C. Eosinophilic pustular folliculitis (Ofuji's disease) with response to dapsone therapy. Arch Dermatol 1985; 121:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/42\">",
"      Malanin G, Helander I. Eosinophilic pustular folliculitis (Ofuji's disease): response to dapsone but not to isotretinoin therapy. J Am Acad Dermatol 1989; 20:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/43\">",
"      Bozeman PM, Learn DB, Thomas EL. Assay of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase. J Immunol Methods 1990; 126:125.",
"     </a>",
"    </li>",
"    <li>",
"     Freedberg IM, Eisen AZ, Wolff K, et al. Fitzpatrick's Dermatology in General Medicine, 6th ed, McGraw-Hill, New York 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24359/abstract/45\">",
"      Handa S, Bingham JS. Dermatological immune restoration syndrome: does it exist? J Eur Acad Dermatol Venereol 2001; 15:430.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4032 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-2EE9D05621-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_50_24359=[""].join("\n");
var outline_f23_50_24359=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antihistamines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Itraconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Topical calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Topical permethrin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Retinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Phototherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Metronidazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dapsone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Oral glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/4032\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4032|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/37/20053\" title=\"picture 1A\">",
"      HIV-associated eosinophilic folliculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/2/33839\" title=\"picture 1B\">",
"      Eosinophilic folliculitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/11/42175\" title=\"picture 2\">",
"      Pruritic papular eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/19/33075\" title=\"picture 3A\">",
"      Eosinophilic folliculitis histology low power view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/35/1590\" title=\"picture 3B\">",
"      Eosinophilic folliculitis histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4032|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28423?source=related_link\">",
"      Approach to the patient with pustular skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22387?source=related_link\">",
"      Folliculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/42/22184?source=related_link\">",
"      Oral isotretinoin therapy for acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_50_24360="Exanthematous (morbilliform) drug eruption";
var content_f23_50_24360=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Exanthematous (morbilliform) drug eruption",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/50/24360/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/50/24360/contributors\">",
"     Andreas J Bircher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/50/24360/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/50/24360/contributors\">",
"     Maja Mockenhaupt, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/50/24360/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/50/24360/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/50/24360/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14870341\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exanthematous drug eruptions, also called morbilliform or maculopapular drug eruptions, are the most common type of adverse drug reaction. They are characterized by a diffuse and symmetric eruption of erythematous macules or small papules occurring approximately one week after the initiation of drug treatment. In severe forms, the mucosae (oral, conjunctival, nasal, or anogenital) and skin appendages (hair and nails) may be involved.",
"   </p>",
"   <p>",
"    This topic will discuss exanthematous drug eruptions. Drug allergy and other types of cutaneous adverse drug reactions are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=see_link\">",
"       \"Drug allergy: Classification and clinical features\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"       \"Allergy to penicillins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11130?source=see_link\">",
"       \"Cephalosporin allergy: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2698?source=see_link\">",
"       \"Hypersensitivity reactions to macrolides, aminoglycosides, tetracyclines, clindamycin, and metronidazole\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8553?source=see_link\">",
"       \"Hypersensitivity reactions to fluoroquinolones antimicrobials\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23594?source=see_link\">",
"       \"Sulfonamide allergy in non HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/50/9000?source=see_link\">",
"       \"Fixed drug eruption\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43929?source=see_link\">",
"       \"Drug reaction with eosinophilia and systemic symptoms (DRESS)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/60/42951?source=see_link\">",
"       \"Acute generalized exanthematous pustulosis (AGEP)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3848?source=see_link\">",
"       \"Lichenoid drug eruption (drug-induced lichen planus)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9322?source=see_link\">",
"       \"Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33801?source=see_link\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1845178\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous drug reactions are estimated to occur in approximately 2 percent of individuals exposed to drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/1\">",
"     1",
"    </a>",
"    ]. The morbilliform exanthem accounts for approximately 95 percent of cutaneous drug reactions and drug urticaria for approximately 5 percent. Drug-specific reaction rates range from zero to greater than 5 percent among exposed patients, with the highest rates reported for antibiotics (1 to 8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14870143\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55253974\">",
"    <span class=\"h2\">",
"     Immunologic mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many, but not all, cases of drug exanthem are thought to be delayed type T-cell mediated (type IV) immune reactions, which involve the activation of several other cell types, such as macrophages, eosinophils, or neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/3\">",
"     3",
"    </a>",
"    ]. The precise mechanisms by which drugs elicit a specific immune response are not completely understood and may involve different types of interaction between drugs and the immune system (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38456?source=see_link&amp;anchor=H2#H2\">",
"     \"Drug allergy: Pathogenesis\", section on 'Interaction of drugs with the immune system'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drugs may act as haptens, form covalent bonds with a protein or peptide, and become antigenic. Haptenated proteins are then processed by antigen presenting cells (APC) to produce haptenated peptides presented on MHC molecules.",
"     </li>",
"     <li>",
"      Drugs may directly interact with immune receptors and activate specific immune cells (the &ldquo;p-i concept&rdquo; or pharmacological interactions of drugs with immune receptors). According to the p-i concept, chemically inert drugs, unable to bind covalently to peptides or proteins, can activate certain T-cells if they fit with sufficient affinity into T-cell receptors or MHC-molecules.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In delayed type immune reactions, specific T-cell clones of the CD4 Th1 or Th2 and CD8 subtypes orchestrate different forms of inflammation depending upon the cytokines produced and other types of cells that become involved, leading to four subcategories of type IV reactions (IVa to IVd) (",
"    <a class=\"graphic graphic_figure graphicRef75626 \" href=\"UTD.htm?8/5/8280\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/5\">",
"     5",
"    </a>",
"    ]. Effector cells such as CD4 Th1 lymphocytes, CD8 cytotoxic lymphocytes, macrophages, and non-specific effector cells such as neutrophils and eosinophils may be involved in the elicitation phase, explaining some of the variability of the clinical manifestations of drug reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exanthematous drug reactions appear to be driven by type IVc reactions, in which T cells act as effector cells. CD8 effector T cells emigrate to tissues and kill cells in a",
"    <span class=\"nowrap\">",
"     perforin/granzyme",
"    </span>",
"    B-, granulysin-, and FasL-directed manner [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/8\">",
"     8",
"    </a>",
"    ]. Type IVc reactions also may occur in other drug hypersensitivity reactions, mostly in conjunction with other type IV reactions involving the recruitment and activation of monocytes, eosinophils, or PMNs. Immunohistochemical and functional studies of drug-reactive T cells in patients with distinct forms of exanthems reveal that distinct T cell functions lead to different clinical phenotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The chronology of the onset and evolution of the skin lesions allows an approximate estimation of what type of pathomechanism and which drugs may be involved, and may be helpful in clinical practice (",
"    <a class=\"graphic graphic_table graphicRef77196 \" href=\"UTD.htm?20/29/20957\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef86511 \" href=\"UTD.htm?19/35/20031\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55254030\">",
"    <span class=\"h2\">",
"     Eliciting drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of drugs may induce delayed type T-cell mediated immune reactions. Some drugs act as haptens, bind to macromolecules, and then become full antigens. Examples include penicillins, cephalosporins, and agents with sulfhydryl groups. The exact antigen is not known for macrolides, quinolones, and tuberculostatic agents.",
"   </p>",
"   <p>",
"    For other drugs, biotransformation is necessary to form reactive metabolites. Examples include the aromatic sulfonamides (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ), anticonvulsant drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , some NSAIDs, and paracetamol. Biotransformation also may be necessary for reverse transcriptase inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    , although the exact mechanism is not known.",
"   </p>",
"   <p>",
"    Drugs that have been introduced within a time frame of three to four&nbsp;weeks before the reaction are more likely to be involved than drugs that have been taken for months or even years, at least when taken in an uninterrupted manner.",
"   </p>",
"   <p>",
"    Sensitization is more likely to occur with topical, intradermal, or subcutaneous exposure than with oral or intravenous exposure. The risk of sensitization is higher with intermittent administration than with long-term, continuous treatment.",
"   </p>",
"   <p>",
"    On-line resources (available by subscription) provide continuously updated, searchable, lists of eliciting drugs, types of exanthemas, and approximate rates of reacting patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13763028\">",
"    <span class=\"h1\">",
"     GENETIC PREDISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacogenetic studies based upon the frequency of some specific HLA alleles suggest that there is a genetic predisposition to drug allergy. In some populations, individuals with HLA-B*1502, HLA-B*5801, or HLA-B*5701 have an increased risk of developing severe drug reactions (eg, Stevens-Johnson syndrome and toxic epidermal necrolysis) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    , respectively (",
"    <a class=\"graphic graphic_table graphicRef76186 \" href=\"UTD.htm?5/58/6059\">",
"     table 2",
"    </a>",
"    ). In European populations, HLA-A*3101 has been associated with a higher incidence of severe drug reactions and maculopapular exanthems to carbamazepine [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H5408138#H5408138\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Adverse events'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=see_link&amp;anchor=H11#H11\">",
"     \"An approach to the patient with drug allergy\", section on 'HLA type'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29586411\">",
"    <span class=\"h1\">",
"     CONTRIBUTING FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13762867\">",
"    <span class=\"h2\">",
"     Underlying disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concomitant diseases may predispose to the development of allergic drug reactions, presumably by altering metabolic pathways or inducing variations in the immunologic responses to drugs. Viral infections, particularly Epstein-Barr virus, cytomegalovirus, and human herpesviruses 6 and 7 are associated with an increased risk of cutaneous drug eruptions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Patients with inborn, acquired, or iatrogenic immunodeficiency, including HIV infection, cystic fibrosis, and autoimmune disorders, also are prone to develop drug-induced exanthems [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/12,15,16\">",
"     12,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13762874\">",
"    <span class=\"h2\">",
"     Co-medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concomitant administration of multiple medications may result in a more frequent occurrence of drug-induced exanthems, although the specific pathomechanism is unclear. Hypersensitivity reactions have been reported in patients treated with high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    , resulting in sensitization to one molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15255950\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exanthematous drug eruptions are characterized by a subtle vacuolar interface dermatitis with scattered dyskeratotic keratinocytes along the dermoepidermal junction (",
"    <a class=\"graphic graphic_picture graphicRef86550 \" href=\"UTD.htm?15/27/15801\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/18\">",
"     18",
"    </a>",
"    ]. Usually, there is a superficial perivascular and interstitial infiltrate of lymphocytes, neutrophils, and eosinophils. Additional features include a pronounced extravasation of erythrocytes, foci of lymphocytes aligned along the dermoepidermal junction, and fibrin deposition within the blood vessel walls of the papillary plexus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14870356\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H198167900\">",
"    <span class=\"h2\">",
"     General features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exanthematous drug eruptions present with erythematous macules, papules, and rarely pustules or bullae, that predominantly involve the trunk and proximal extremities (",
"    <a class=\"graphic graphic_picture graphicRef86509 graphicRef54205 graphicRef70062 graphicRef86552 \" href=\"UTD.htm?27/10/27818\">",
"     picture 2A-D",
"    </a>",
"    ). In mild forms, acral sites are most often spared, although the face, palms, and soles may be involved.",
"   </p>",
"   <p>",
"    Drug-induced exanthems are often described as &ldquo;morbilliform&rdquo; or &ldquo;rubelliform&rdquo; because the lesion morphology and distribution pattern closely resemble those of viral exanthems [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/6\">",
"     6",
"    </a>",
"    ]. However, in some cases there is a profuse eruption of small papules that does not resemble any infective exanthem. Purpuric lesions may develop on the legs and other dependent areas.",
"   </p>",
"   <p>",
"    Systemic symptoms include pruritus, low-grade fever, elevation of acute-phase proteins, and mild eosinophilia.",
"   </p>",
"   <p>",
"    The eruption usually develops within 5 to 14 days of treatment, but may occur within one or two days in previously sensitized individuals. In patients taking antibiotics, the eruption may appear up to several days after the treatment has been stopped.",
"   </p>",
"   <p>",
"    Mucosal involvement is usually absent in uncomplicated drug exanthems. If the oral, genital, or other mucosae are involved, more severe drug hypersensitivity reactions (eg, drug rash with eosinophilia and systemic symptoms [DRESS] syndrome or",
"    <span class=\"nowrap\">",
"     Stevens-Johnson/toxic",
"    </span>",
"    epidermal necrolysis) should be suspected. (See",
"    <a class=\"local\" href=\"#H14870363\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1366656\">",
"    <span class=\"h2\">",
"     Intertriginous and flexural localization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symmetrical drug-related intertriginous and flexural exanthem (SDRIFE), formerly called baboon syndrome, is an uncommon variant of exanthematous drug eruption, most often induced by aminopenicillins (",
"    <a class=\"graphic graphic_picture graphicRef86506 \" href=\"UTD.htm?5/44/5824\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/19\">",
"     19",
"    </a>",
"    ]. In rare instances, SDRIFE can be the manifestation of systemically elicited allergic contact dermatitis to nickel or mercury [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SDRIFE occurs a few hours to a few days after the administration of the offending drug (",
"    <a class=\"graphic graphic_figure graphicRef86511 \" href=\"UTD.htm?19/35/20031\">",
"     figure 2",
"    </a>",
"    ). The rash presents as a sharply demarcated V-shaped erythema in the",
"    <span class=\"nowrap\">",
"     gluteal/perianal",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     inguinal/perigenital",
"    </span>",
"    areas, often with involvement of at least one other flexural area such as the axillae, elbows, or knees (",
"    <a class=\"graphic graphic_picture graphicRef86506 \" href=\"UTD.htm?5/44/5824\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/6,19,21\">",
"     6,19,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71017118\">",
"    <span class=\"h2\">",
"     Early signs of severe reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;An exanthematous drug eruption rarely may be the heralding sign of a severe hypersensitivity reaction, such as acute generalized exanthematous pustulosis (AGEP), drug rash with eosinophilia and systemic symptoms (DRESS), or Stevens-Johnson",
"    <span class=\"nowrap\">",
"     syndrome/toxic",
"    </span>",
"    necrolysis",
"    <span class=\"nowrap\">",
"     (SJS/TEN)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/60/42951?source=see_link\">",
"     \"Acute generalized exanthematous pustulosis (AGEP)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43929?source=see_link\">",
"     \"Drug reaction with eosinophilia and systemic symptoms (DRESS)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Warning signs of severe cutaneous hypersensitivity reaction include evolution to erythroderma, fever &gt;38&deg;C (100.4&deg;F), facial edema, mucositis, skin tenderness, or blistering (",
"    <a class=\"graphic graphic_table graphicRef86557 \" href=\"UTD.htm?36/8/37004\">",
"     table 3",
"    </a>",
"    ). Patients should be advised that if any of these signs occur, they should seek immediate medical attention. (See",
"    <a class=\"local\" href=\"#H198168284\">",
"     'Patient education'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45737162\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most exanthematous drug eruptions are of mild to moderate severity and do not cause major morbidity. The eruption evolves rapidly, reaches the maximal extent approximately two days after the elimination of the causative drug, and resolves in 7 to 14 days (",
"    <a class=\"graphic graphic_figure graphicRef86511 \" href=\"UTD.htm?19/35/20031\">",
"     figure 2",
"    </a>",
"    ). Occasionally, the eruption subsides despite continuation of the medication.",
"   </p>",
"   <p>",
"    Resolution often occurs with desquamation. In patients with darker skin tones, postinflammatory hyperpigmentation can occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55253960\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14324195\">",
"    <span class=\"h2\">",
"     Clinical diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of exanthematous drug eruption is suspected in a patient receiving drug treatment who presents with a recent onset rash. The clinical suspicion can be substantiated by history, clinical features, laboratory testing, and sometimes by histopathologic examination of a skin biopsy.",
"   </p>",
"   <p>",
"    Key elements for the clinical diagnosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Medication history",
"      </strong>",
"      &ndash; The patient should be questioned about current and past medications, including over-the-counter drugs and topical preparations. Establishing a chronologic relationship between drug exposure and onset of the rash is crucial to the identification of the culprit drug (",
"      <a class=\"graphic graphic_table graphicRef86515 \" href=\"UTD.htm?41/2/42028\">",
"       table 4",
"      </a>",
"      ). Sensitization to a drug may have taken place with a past exposure to the same drug or to a cross-reacting drug. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=see_link&amp;anchor=H17#H17\">",
"       \"An approach to the patient with drug allergy\", section on 'Identification of the suspect drug'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Resolution of the rash after drug withdrawal",
"      </strong>",
"      &ndash; The eruption typically clears rapidly (usually within 7 to 14 days) after the suspected drug is discontinued.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since most drug exanthems appear within the first week after starting a drug treatment, the diagnosis is often straightforward. However, anticonvulsants, antibiotics, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    may induce rashes up to three weeks after initiation of therapy.",
"   </p>",
"   <p>",
"    Identifying a particular drug as the cause of an eruption is difficult when the patient is taking multiple drugs. In this situation, it may be helpful to know the relative frequencies of cutaneous reactions for specific agents (",
"    <a class=\"graphic graphic_table graphicRef86585 \" href=\"UTD.htm?36/54/37740\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/1,2,24-26\">",
"     1,2,24-26",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In patients with a previous history of drug eruption, accidental reexposure should be investigated, given the increased use of generic medications with the same active ingredients but different brand names. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14324138\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory evaluation of patients with suspected drug-induced exanthem generally is not necessary. However, laboratory evaluation may be necessary if the clinical diagnosis is uncertain. It may include general laboratory tests, specific immunologic tests, and possibly a skin biopsy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General laboratory tests may include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Complete blood cell count with differential (looking for eosinophilia which supports the diagnosis, but also occurs in patients with drug rash with eosinophilia and systemic symptoms [DRESS])",
"     </li>",
"     <li>",
"      Liver and kidney function tests (looking for systemic involvement which may occur in patients with DRESS)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antinuclear autoantibody tests should be performed if an autoimmune connective tissue disease is suspected (eg, juvenile idiopathic arthritis, lupus erythematosus)",
"     </li>",
"     <li>",
"      Specific immunologic tests to evaluate delayed drug reactions may be performed one to six months after the complete resolution of the clinical symptoms and include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patch testing",
"     </li>",
"     <li>",
"      Intradermal testing with delayed cutaneous readouts",
"     </li>",
"     <li>",
"      In vitro tests for delayed reactions (eg, lymphocyte",
"      <span class=\"nowrap\">",
"       transformation/activation",
"      </span>",
"      tests, upregulation of activation markers on T cells, cytokine production, and drug-induced cytotoxicity assays)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tests for delayed hypersensitivity are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=see_link&amp;anchor=H29#H29\">",
"     \"An approach to the patient with drug allergy\", section on 'Type IV reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H198168590\">",
"    <span class=\"h2\">",
"     Skin biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin biopsy is not routinely necessary to make the diagnosis of exanthematous drug eruption. However, a skin biopsy for histologic examination may be warranted if the diagnosis is uncertain or if there is concern for a severe hypersensitivity reaction. (See",
"    <a class=\"local\" href=\"#H15255950\">",
"     'Histopathology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H71017118\">",
"     'Early signs of severe reaction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14870363\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Potential indications for skin biopsy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple drugs involved without a clear-cut temporal relationship with cutaneous reaction",
"     </li>",
"     <li>",
"      Severe systemic symptoms (eg, fever &gt;38&deg;C (100.4&deg;F),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptoms of internal organ involvement)",
"     </li>",
"     <li>",
"      Evolution to erythroderma, blistering, purpura, or pustulation",
"     </li>",
"     <li>",
"      Mucous membrane involvement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The finding of vacuolar interface dermatitis and tissue eosinophilia supports the diagnosis of exanthematous drug eruption (",
"    <a class=\"graphic graphic_picture graphicRef86550 \" href=\"UTD.htm?15/27/15801\">",
"     picture 1",
"    </a>",
"    ), but is nonspecific [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14870363\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of exanthematous drug eruption includes viral and bacterial exanthems, rashes associated with systemic diseases, and cutaneous diseases (",
"    <a class=\"graphic graphic_table graphicRef86513 \" href=\"UTD.htm?30/33/31260\">",
"     table 6",
"    </a>",
"    ). The morphology, distribution, and spatial and temporal evolution of the rash and laboratory tests (eg, antinuclear antibody tests) may help in distinguishing a drug-induced exanthem from viral or bacterial exanthems or rashes associated with systemic or cutaneous diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/7,27,28\">",
"     7,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evolution of the rash and clinical course distinguishes exanthematous drug eruption from more severe hypersensitivity reactions, such as acute generalized exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms and Stevens-Johnson",
"    <span class=\"nowrap\">",
"     syndrome/toxic",
"    </span>",
"    necrolysis",
"    <span class=\"nowrap\">",
"     (SJS/TEN)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef86557 \" href=\"UTD.htm?36/8/37004\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/60/42951?source=see_link\">",
"     \"Acute generalized exanthematous pustulosis (AGEP)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43929?source=see_link\">",
"     \"Drug reaction with eosinophilia and systemic symptoms (DRESS)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14870405\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45737196\">",
"    <span class=\"h2\">",
"     Drug withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt withdrawal of the offending drug is the mainstay of treatment of exanthematous drug eruptions. In patients taking several drugs, nonessential drugs should be discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45737203\">",
"    <span class=\"h2\">",
"     Symptomatic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of exanthematous drug eruptions is largely symptomatic. The efficacy of symptomatic therapies for the treatment of exanthematous drug eruptions has not been evaluated in randomized trials and their use is based upon clinical experience.",
"   </p>",
"   <p>",
"    For symptomatic relief of pruritus, we suggest topical corticosteroids and oral antihistamines. We generally use high potency (group one to three (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 7",
"    </a>",
"    )) topical corticosteroids one to two times per day for one week. Antihistamines include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       Diphenhydramine",
"      </a>",
"      &ndash; 25 to 50 mg orally every four to six hours for adults and children &ge;12 years; 12.5 to 25 mg orally every four to six hours for children 6 to 11 years; and 6.25 mg orally every four to six hours for children two to five years. Diphenhydramine is continued until pruritus subsides.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"       Hydroxyzine",
"      </a>",
"      &ndash; 25 mg orally three to four times per day for adults and children &ge;6 years; 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day orally divided every six to eight hours for children &lt;6 years. Hydroxyzine is continued until pruritus subsides.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"       Cetirizine",
"      </a>",
"      &ndash; 10 mg orally once daily for adults and children &ge;6 years; 2.5 mg once daily for children 12 months to &lt;2 years; 2.5 mg once daily for children 6 to 12 months. Cetirizine is continued until pruritus subsides.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest not using systemic corticosteroids for the treatment of uncomplicated exanthematous drug eruptions. However, in patients with drug-induced rash and systemic or cutaneous symptoms suggesting a severe cutaneous reaction (",
"    <a class=\"graphic graphic_table graphicRef86557 \" href=\"UTD.htm?36/8/37004\">",
"     table 3",
"    </a>",
"    ), a short course of",
"    <span class=\"nowrap\">",
"     moderate/high",
"    </span>",
"    dose systemic corticosteroids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H71017118\">",
"     'Early signs of severe reaction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1367407\">",
"    <span class=\"h2\">",
"     &ldquo;Treating through&rdquo;",
"    </span>",
"    &nbsp;&mdash;&nbsp;&ldquo;Treating through&rdquo; is the continuation of a drug treatment despite the hypersensitivity reaction. This approach is sometimes adopted when the suspected drug is important and no alternative drug is available. &ldquo;Treating through&rdquo; may be associated with progressive worsening of the rash or erythroderma. Comedication with corticosteroids or antihistamines may reduce the risk of progression, but has not been well studied. There is limited evidence from case series of",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    patients treated with cotrimoxazole for prophylaxis or treatment of opportunistic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/30\">",
"     30",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H198168284\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the acute phase of the drug reaction, patients should be educated about warning signs of more severe hypersensitivity reactions. These include high fever, facial edema, mucosal symptoms, skin tenderness, and blistering (",
"    <a class=\"graphic graphic_table graphicRef86557 \" href=\"UTD.htm?36/8/37004\">",
"     table 3",
"    </a>",
"    ). Patients should seek immediate medical attention if any of these signs occur. (See",
"    <a class=\"local\" href=\"#H71017118\">",
"     'Early signs of severe reaction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14870241\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1367579\">",
"    <span class=\"h2\">",
"     Avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be counseled to avoid the offending drug and cross-reacting drugs in the future. They should be provided with a written list of the generic and brand names of the culprit drug, as well as possibly cross-reactive drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=see_link&amp;anchor=H41#H41\">",
"     \"An approach to the patient with drug allergy\", section on 'Long-term management of patients prone to drug allergy'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1367499\">",
"    <span class=\"h2\">",
"     Premedication",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not suggest premedication with corticosteroids and antihistamines for the prevention of exanthematous drug eruption in sensitized patients. The efficacy of prophylactic corticosteroids and antihistamines for preventing a delayed-type drug reaction in sensitized patients has not been evaluated in randomized trials and remains uncertain.",
"   </p>",
"   <p>",
"    Premedication to prevent immediate hypersensitivity reaction to contrast media is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38680?source=see_link&amp;anchor=H2#H2\">",
"     \"Immediate hypersensitivity reactions to radiocontrast media: Prevention of recurrent reactions\", section on 'Preventative measures'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14870248\">",
"    <span class=\"h2\">",
"     Desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization to induce temporary drug tolerance is an established practice only in the management of immediate-type hypersensitivity reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=see_link\">",
"     \"Rapid drug desensitization for immediate hypersensitivity reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is little evidence for efficacy of desensitization in T-cell mediated delayed-type cutaneous hypersensitivity reactions. However, in patients with a history of mild to moderate exanthem who are in repeated need of a drug, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    in HIV infection or antibiotics in cystic fibrosis, desensitization may be an option [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24360/abstract/15,30\">",
"     15,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=see_link&amp;anchor=H40#H40\">",
"     \"An approach to the patient with drug allergy\", section on 'Desensitization to the culprit drug'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1367506\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exanthematous (morbilliform) drug eruptions are the most common type of adverse drug reaction, occurring in approximately 2 percent of individuals exposed to drugs. (See",
"      <a class=\"local\" href=\"#H14870341\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1845178\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many exanthematous drug eruptions are thought to be delayed type T-cell mediated immune reactions. These reactions may occur with a large variety of drugs (",
"      <a class=\"graphic graphic_table graphicRef77196 \" href=\"UTD.htm?20/29/20957\">",
"       table 1",
"      </a>",
"      ). Genetic predisposition, underlying viral diseases (eg, Epstein-Barr virus, human herpesvirus), and the administration of multiple medications increase the risk of exanthematous drug eruption. (See",
"      <a class=\"local\" href=\"#H14870143\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13763028\">",
"       'Genetic predisposition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H29586411\">",
"       'Contributing factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exanthematous drug eruptions are characterized by erythematous macules and papules that predominantly involve the trunk and proximal extremities (",
"      <a class=\"graphic graphic_picture graphicRef86509 graphicRef54205 graphicRef70062 graphicRef86552 \" href=\"UTD.htm?27/10/27818\">",
"       picture 2A-D",
"      </a>",
"      ). Mucosal involvement is usually absent. In most patients, the rash develops within 5 to 14 days of treatment and resolves in 7 to 14 days after drug withdrawal. Systemic symptoms include pruritus, low-grade fever, and mild eosinophilia. (See",
"      <a class=\"local\" href=\"#H14870356\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H45737162\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of exanthematous drug eruption is suspected in patients with a characteristic rash that occurs after recent drug exposure (",
"      <a class=\"graphic graphic_table graphicRef86515 \" href=\"UTD.htm?41/2/42028\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef86509 graphicRef54205 graphicRef70062 graphicRef86552 \" href=\"UTD.htm?27/10/27818\">",
"       picture 2A-D",
"      </a>",
"      ). Resolution of the rash after drug discontinuation supports the diagnosis. Skin biopsy is not necessary to confirm the diagnosis, but may be warranted in uncertain cases. (See",
"      <a class=\"local\" href=\"#H55253960\">",
"       'Diagnosis'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The differential diagnosis of exanthematous drug eruption includes viral and bacterial exanthems, rashes associated with systemic diseases, and cutaneous diseases (",
"      <a class=\"graphic graphic_table graphicRef86513 \" href=\"UTD.htm?30/33/31260\">",
"       table 6",
"      </a>",
"      ). An exanthematous drug eruption rarely may be the heralding sign of more severe hypersensitivity reactions. Warning signs include evolution to erythroderma, high fever, facial edema, mucositis, skin tenderness, and blistering (",
"      <a class=\"graphic graphic_table graphicRef86557 \" href=\"UTD.htm?36/8/37004\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14870363\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H71017118\">",
"       'Early signs of severe reaction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prompt withdrawal of the offending drug is the mainstay of treatment of exanthematous drug eruptions. For symptomatic relief of pruritus, we suggest topical corticosteroids and oral antihistamines (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We generally use high potency (group one to three (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 7",
"      </a>",
"      )) topical corticosteroids one to two times per day for one week. Antihistamines (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"       hydroxyzine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      ) are given orally until pruritus subsides. (See",
"      <a class=\"local\" href=\"#H45737196\">",
"       'Drug withdrawal'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H45737203\">",
"       'Symptomatic treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/1\">",
"      Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256:3358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/2\">",
"      Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001; 137:765.",
"     </a>",
"    </li>",
"    <li>",
"     Pichler WJ. Drug Hypersensitivity Reactions: Classification and Relationship to T-Cell Activation. In: Drug Hypersensitivity, Pichler WJ (Ed), Karger Publishers, Basel 2007. p.168.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/4\">",
"      Adam J, Pichler WJ, Yerly D. Delayed drug hypersensitivity: models of T-cell stimulation. Br J Clin Pharmacol 2011; 71:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/5\">",
"      Lerch M, Pichler WJ. The immunological and clinical spectrum of delayed drug-induced exanthems. Curr Opin Allergy Clin Immunol 2004; 4:411.",
"     </a>",
"    </li>",
"    <li>",
"     Bircher AJ. Uncomplicated drug-induced disseminated exanthemas. In: Chemical Immunology, French L (Ed), Karger Publishers, Basel 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/7\">",
"      Friedmann PS, Pickard C, Ardern-Jones M, Bircher AJ. Drug-induced exanthemata: a source of clinical and intellectual confusion. Eur J Dermatol 2010; 20:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/8\">",
"      Pichler WJ, Adam J, Daubner B, et al. Drug hypersensitivity reactions: pathomechanism and clinical symptoms. Med Clin North Am 2010; 94:645.",
"     </a>",
"    </li>",
"    <li>",
"     Litt JZ. Litt's Drug Eruptions and Reactions Manual, 16th ed, Informa Healthcare, London 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/10\">",
"      Wei CY, Ko TM, Shen CY, Chen YT. A recent update of pharmacogenomics in drug-induced severe skin reactions. Drug Metab Pharmacokinet 2012; 27:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/11\">",
"      Profaizer T, Eckels D. HLA alleles and drug hypersensitivity reactions. Int J Immunogenet 2012; 39:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/12\">",
"      Stokes SC, Tankersley MS. HIV: practical implications for the practicing allergist-immunologist. Ann Allergy Asthma Immunol 2011; 107:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/13\">",
"      Tohyama M, Hashimoto K. New aspects of drug-induced hypersensitivity syndrome. J Dermatol 2011; 38:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/14\">",
"      Aota N, Shiohara T. Viral connection between drug rashes and autoimmune diseases: how autoimmune responses are generated after resolution of drug rashes. Autoimmun Rev 2009; 8:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/15\">",
"      Whitaker P, Shaw N, Gooi J, et al. Rapid desensitization for non-immediate reactions in patients with cystic fibrosis. J Cyst Fibros 2011; 10:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/16\">",
"      Spoerl D, Scherer K, Tyndall A. Aspects of allergy in rheumatology. Clin Exp Rheumatol 2011; 29:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/17\">",
"      Schaub N, Bircher AJ. Severe hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro. Allergy 2000; 55:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/18\">",
"      Justiniano H, Berlingeri-Ramos AC, S&aacute;nchez JL. Pattern analysis of drug-induced skin diseases. Am J Dermatopathol 2008; 30:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/19\">",
"      H&auml;usermann P, Harr T, Bircher AJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? Contact Dermatitis 2004; 51:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/20\">",
"      Lerch M, Bircher AJ. Systemically induced allergic exanthem from mercury. Contact Dermatitis 2004; 50:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/21\">",
"      Tan SC, Tan JW. Symmetrical drug-related intertriginous and flexural exanthema. Curr Opin Allergy Clin Immunol 2011; 11:313.",
"     </a>",
"    </li>",
"    <li>",
"     Scherer K, Bircher AJ. Danger Signs in Drug Hypersensitivity. In: Drug Hypersensitivity, Pichler WJ (Ed), W.B. Saunders Co., Philadelphia 2010. p.681.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/23\">",
"      Bircher AJ. Symptoms and danger signs in acute drug hypersensitivity. Toxicology 2005; 209:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/24\">",
"      van der Linden PD, van der Lei J, Vlug AE, Stricker BH. Skin reactions to antibacterial agents in general practice. J Clin Epidemiol 1998; 51:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/25\">",
"      Kulthanan K, Chularojanamontri L, Manapajon A, et al. Cutaneous adverse reactions to fluoroquinolones. Dermatitis 2011; 22:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/26\">",
"      Lange-Asschenfeldt C, Grohmann R, Lange-Asschenfeldt B, et al. Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program. J Clin Psychiatry 2009; 70:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/27\">",
"      Drago F, Rampini E, Rebora A. Atypical exanthems: morphology and laboratory investigations may lead to an aetiological diagnosis in about 70% of cases. Br J Dermatol 2002; 147:255.",
"     </a>",
"    </li>",
"    <li>",
"     Bircher AJ. Approach to the patient with a drug hypersensitivity reaction - clinical perspectives. In: Drug Hypersensitivity, Pichler WJ (Ed), Karger Publishers, Basel 2007. p.352.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/29\">",
"      Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/30\">",
"      Lin D, Li WK, Rieder MJ. Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole. Cochrane Database Syst Rev 2007; :CD005646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24360/abstract/31\">",
"      Cernadas JR, Brockow K, Romano A, et al. General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy 2010; 65:1357.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15762 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-188.40.116.55-6D8648E745-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_50_24360=[""].join("\n");
var outline_f23_50_24360=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1367506\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14870341\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1845178\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14870143\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55253974\">",
"      Immunologic mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55254030\">",
"      Eliciting drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13763028\">",
"      GENETIC PREDISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29586411\">",
"      CONTRIBUTING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13762867\">",
"      Underlying disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13762874\">",
"      Co-medication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15255950\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14870356\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H198167900\">",
"      General features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1366656\">",
"      Intertriginous and flexural localization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H71017118\">",
"      Early signs of severe reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45737162\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H55253960\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14324195\">",
"      Clinical diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14324138\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H198168590\">",
"      Skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14870363\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14870405\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45737196\">",
"      Drug withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45737203\">",
"      Symptomatic treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1367407\">",
"      &ldquo;Treating through&rdquo;",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H198168284\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14870241\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1367579\">",
"      Avoidance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1367499\">",
"      Premedication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14870248\">",
"      Desensitization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1367506\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15762\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15762|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/5/8280\" title=\"figure 1\">",
"      Gell Coombs IVa-d",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/35/20031\" title=\"figure 2\">",
"      Drug eruption chronology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15762|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/27/15801\" title=\"picture 1\">",
"      Morbilliform drug eruption histo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/33/3601\" title=\"picture 2A\">",
"      Exanthematous drug eruption - Back",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/6/37985\" title=\"picture 2B\">",
"      Morbilliform drug eruption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/30/32239\" title=\"picture 2C\">",
"      Morbilliform eruption 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/41/35477\" title=\"picture 2D\">",
"      Exanthematous drug eruption dark skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/44/5824\" title=\"picture 3\">",
"      SDRIFE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15762|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/29/20957\" title=\"table 1\">",
"      Immunologic sys drug rxns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/58/6059\" title=\"table 2\">",
"      SJSTEN risk HLA type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/8/37004\" title=\"table 3\">",
"      Severe drug eruptions ddx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/2/42028\" title=\"table 4\">",
"      Drug eruptions clin manifestations and chronology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/54/37740\" title=\"table 5\">",
"      Rates of cutaneous drug reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/33/31260\" title=\"table 6\">",
"      Exanthematous drug eruption ddx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 7\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9322?source=related_link\">",
"      Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/60/42951?source=related_link\">",
"      Acute generalized exanthematous pustulosis (AGEP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=related_link\">",
"      An approach to the patient with drug allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11130?source=related_link\">",
"      Cephalosporin allergy: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=related_link\">",
"      Drug allergy: Classification and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/35/38456?source=related_link\">",
"      Drug allergy: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43929?source=related_link\">",
"      Drug reaction with eosinophilia and systemic symptoms (DRESS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/50/9000?source=related_link\">",
"      Fixed drug eruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/22/8553?source=related_link\">",
"      Hypersensitivity reactions to fluoroquinolones antimicrobials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2698?source=related_link\">",
"      Hypersensitivity reactions to macrolides, aminoglycosides, tetracyclines, clindamycin, and metronidazole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38680?source=related_link\">",
"      Immediate hypersensitivity reactions to radiocontrast media: Prevention of recurrent reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/48/3848?source=related_link\">",
"      Lichenoid drug eruption (drug-induced lichen planus)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29672?source=related_link\">",
"      Rapid drug desensitization for immediate hypersensitivity reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33801?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23594?source=related_link\">",
"      Sulfonamide allergy in non HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_50_24361="Intermediate case 12 answer";
var content_f23_50_24361=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Atrial flutter with 2:1 block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical atrial flutter with 2:1 atrioventricular block. The flutter rate is approximately 300/min with a ventricular rate of 150/min. The flutter waves are best seen in leads II, III, and V1 (arrows). This patient also has low QRS voltage in the limb leads, a non-specific finding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_50_24361=[""].join("\n");
var outline_f23_50_24361=null;
var title_f23_50_24362="General principles of the implantable cardioverter-defibrillator";
var content_f23_50_24362=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General principles of the implantable cardioverter-defibrillator",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/50/24362/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/50/24362/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/50/24362/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/50/24362/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/50/24362/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/50/24362/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/50/24362/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular fibrillation (VF) is a common cause of sudden cardiac death (SCD) and is sometimes preceded by monomorphic or polymorphic ventricular tachycardia (VT). Although cardiopulmonary resuscitation, including chest compressions and assisted ventilation, can provide transient circulatory support for the patient with cardiac arrest, the only effective approach for terminating VF is electrical defibrillation. Success with external defibrillation led to the development of an implantable defibrillator in the mid-1960s. It was not until 1980 that the first automatic internal defibrillator was implanted in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since that time, there has been a dramatic increase in the use of the implantable cardioverter-defibrillator (ICD) to monitor for",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    and to provide prompt treatment. Because of its high success rate in terminating",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    rapidly, results of multiple clinical trials showing improvement in survival, ICD implantation is generally considered the first-line treatment option for the secondary prevention of SCD and for primary prevention in certain populations at high risk of SCD due to",
"    <span class=\"nowrap\">",
"     VT/VF.",
"    </span>",
"    Alternatives to ICD implantation include antiarrhythmic drugs, ablative surgery, transcatheter ablation, and, in selected individuals, cardiac transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the general indications for ICD implantation, the elements of the ICD, the features of ICD therapy and programming, and the role of adjunctive therapies in patients who receive an ICD. The clinical trials documenting the efficacy of an ICD in different clinical settings (including both secondary and primary prevention), complications of ICD placement, and follow-up care of patients with ICDs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30599?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39672?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Patient follow-up\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SUMMARY OF INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main indications for use of an ICD relate to secondary prevention in patients with prior ventricular tachycardia (VT), ventricular fibrillation (VF), or resuscitated sudden cardiac death (SCD) as well as primary prevention in patients at increased risk of",
"    <span class=\"nowrap\">",
"     VT/VF.",
"    </span>",
"    The 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    guidelines for device-based therapy of cardiac rhythm abnormalities include guidelines for ICD therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Indications for ICD therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1316894748\">",
"    <span class=\"h3\">",
"     Secondary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Implantation of an ICD is recommended for the secondary prevention of",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    in the following settings [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a prior episode of resuscitated",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      or sustained hemodynamically unstable VT in whom a completely reversible cause cannot be identified. This includes patients with a variety of underlying heart diseases and those with idiopathic",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      and congenital long QT syndrome, but",
"      <strong>",
"       not",
"      </strong>",
"      patients who have",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      limited to the first 48 hours after an acute MI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"       \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"       \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30041?source=see_link\">",
"       \"Outcome of sudden cardiac arrest\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with episodes of spontaneous sustained VT in the presence of heart disease (valvular, ischemic, hypertrophic, dilated, or infiltrative cardiomyopathies) and other settings (eg, channelopathies). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=see_link&amp;anchor=H12#H12\">",
"       \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\", section on 'ICD therapy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link\">",
"       \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A key issue is the prevention of total mortality (not arrhythmic or sudden death). Simply correcting",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    may not do this. Therefore, patient selection for an ICD should take into account both the known risk of SCD due to",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    for a specific condition and the risk of total mortality from underlying medical conditions as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1316894755\">",
"    <span class=\"h3\">",
"     Primary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Implantation of an ICD is recommended for the primary prevention of",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    in patients at risk of SCD due to",
"    <span class=\"nowrap\">",
"     VT/VF",
"    </span>",
"    who have optimal medical management (including use of beta blockers and ACE inhibitors), including [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a prior myocardial infarction (at least 40 days ago) and left ventricular ejection fraction &le;30 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link&amp;anchor=H29#H29\">",
"       \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\", section on 'ICD therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a cardiomyopathy, New York Heart Association functional class II to III (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ), and left ventricular ejection fraction &le;35 percent. Patients with a nonischemic cardiomyopathy generally require optimal medical therapy for three months with documentation of persistent left ventricular ejection fraction &le;35 percent at that time. It is recommended that patients be evaluated at least three months after revascularization (CABG or stent placement). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H26#H26\">",
"       \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients with heart failure who are candidates for an ICD also have intraventricular conduction delay (&ge;120 ms) and are candidates for cardiac resynchronization therapy with a biventricular pacemaker. Such patients could be treated with a device with combined ICD and biventricular pacing functions. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Cardiac resynchronization therapy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with syncope who have structural heart disease and inducible",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      on electrophysiology study. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28855?source=see_link&amp;anchor=H11#H11\">",
"       \"Management of the patient with syncope\", section on 'Supraventricular arrhythmias'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Select patients with certain underlying disorders who are deemed to be at high risk for life-threatening",
"      <span class=\"nowrap\">",
"       VT/VF.",
"      </span>",
"      This includes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with congenital long QT syndrome who have recurrent symptoms or torsades de pointes despite therapy with beta blockers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=see_link&amp;anchor=H36#H36\">",
"       \"Prognosis and management of congenital long QT syndrome\", section on 'Role of ICD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      High-risk patients with hypertrophic cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link&amp;anchor=H11#H11\">",
"       \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\", section on 'Identifying high-risk patients'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      High-risk patients with Brugada syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"       \"Brugada syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      High-risk patients with arrhythmogenic right ventricular cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy\", section on 'Role of ICD'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     When ICD therapy is not indicated",
"    </span>",
"    &nbsp;&mdash;&nbsp;ICD therapy is",
"    <strong>",
"     NOT",
"    </strong>",
"    recommended in the following settings [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with ventricular tachyarrhythmias due to a completely reversible disorder in the absence of structural heart disease (eg, electrolyte imbalance, drugs, or trauma).",
"     </li>",
"     <li>",
"      Patients who do not have a reasonable expectation of survival with an acceptable functional status for at least one year, even if they otherwise meet ICD implantation criteria.",
"     </li>",
"     <li>",
"      Patients with incessant ventricular tachycardia (VT) or ventricular fibrillation (VF). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/23/376?source=see_link\">",
"       \"Electrical storm and incessant ventricular tachycardia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with significant psychiatric illnesses that may be aggravated by device implantation or that may preclude systematic follow-up.",
"     </li>",
"     <li>",
"      Patients with NYHA Class IV heart failure that is refractory to optimal medical treatment who are not candidates for cardiac transplantation or cardiac resynchronization therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=see_link\">",
"       \"Indications and contraindications for cardiac transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"       \"Cardiac resynchronization therapy in heart failure: Indications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with syncope without inducible ventricular tachyarrhythmias and without structural heart disease.",
"     </li>",
"     <li>",
"      Patient with VF or VT amenable to surgical or catheter ablation (eg, atrial arrhythmias associated with the Wolff-Parkinson-White syndrome, right ventricular or left ventricular outflow tract VT, idiopathic VT or fascicular VT in the absence of structural heart disease). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=see_link\">",
"       \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ELEMENTS OF THE ICD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ICD system is comprised of three elements [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Pacing/sensing",
"      </span>",
"      electrodes",
"     </li>",
"     <li>",
"      Defibrillation electrodes",
"     </li>",
"     <li>",
"      Pulse generator",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contemporary transvenous ICDs, both the",
"    <span class=\"nowrap\">",
"     pace/sense",
"    </span>",
"    electrodes and the defibrillation electrodes are located on a single ventricular lead.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pace/sense electrodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pacing and sensing functions require a pair of electrodes. Many older pacemaker and ICD leads have a single electrode at the tip of the ventricular lead (ie, unipolar leads). Such leads use the metal housing of the pulse generator as the second electrode. Contemporary pacemakers and defibrillators usually use leads with two electrodes on the ventricular lead - the distal electrode at the tip of the lead and a second electrode in the shape of a ring, several millimeters back from the tip (ie, bipolar leads). These bipolar leads provide more accurate sensing, with high amplitude, narrow electrograms. Some ICD leads utilize integrated bipolar sensing in which the bipole consists of a single tip electrode and the distal shocking coil electrode. In addition to improved sensing capabilities, bipolar leads reduce the risk of extraneous interference which could lead to inappropriate device function (eg, inappropriate shocks delivered due to sensing of muscular activity).",
"   </p>",
"   <p>",
"    In most new ICD implantations, the lead with the",
"    <span class=\"nowrap\">",
"     pace/sense",
"    </span>",
"    electrodes is placed transvenously, with the distal electrode positioned on the right ventricular apical endocardium. In rare cases, usually due to limitations of the venous anatomy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a high risk of bacteremia and endovascular infection, the",
"    <span class=\"nowrap\">",
"     pace/sense",
"    </span>",
"    electrodes are placed on the epicardium during surgery (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56923 \" href=\"UTD.htm?40/53/41813\">",
"     image 1",
"    </a>",
"    ). The electrodes should record a ventricular electrogram of at least 5 mV. These signals should be sufficiently large for detection of ventricular tachycardia and fibrillation.",
"   </p>",
"   <p>",
"    Dual-chamber ICDs have an additional lead with another pair of",
"    <span class=\"nowrap\">",
"     pace/sense",
"    </span>",
"    electrodes in the right atrium for atrial sensing and pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link&amp;anchor=H15#H15\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\", section on 'Pacing modes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Defibrillation electrodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The defibrillation electrodes have a relatively large surface area and are positioned to maximize the density of current flow through the ventricular myocardium. Contemporary ICD systems use a \"coil\" of wire that extends along the ventricular lead as the primary defibrillation electrode. Thus, a single transvenous lead can accomplish all pacing, sensing and defibrillation functions. In the past, epicardial patches were used for defibrillation, but placement required a thoracotomy.",
"   </p>",
"   <p>",
"    Additional defibrillation electrodes improve defibrillation efficacy and reduce the defibrillation threshold. Most contemporary ICD systems have two or three defibrillation electrodes. Along with the distal coil in the right ventricle on the transvenous lead, some ICD leads have a second defibrillation coil proximal to the right ventricular coil. In addition, with \"active can\" technology, the metal housing of the ICD serves as one of the shocking electrodes. This configuration requires that the pulse generator be implanted in the pectoral region (",
"    <a class=\"graphic graphic_figure graphicRef74224 \" href=\"UTD.htm?23/23/23925\">",
"     figure 1",
"    </a>",
"    ). The active can and transvenous lead systems can be combined to achieve adequate defibrillation thresholds (minimum energy required for successful defibrillation, which should generally be 10 joules less than the maximum output of the device).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pulse generator",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulse generator contains the sensing circuitry as well as the high voltage capacitors and battery. The development of small pulse generators (eg, thickness &le;15 mm) has permitted pectoral implantation in nearly all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/6\">",
"     6",
"    </a>",
"    ]. A pulse generator will last for five or more years in most patients, with one study suggesting that devices implanted after 2002 have significantly longer battery lives (5.6 versus 4.9 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/7\">",
"     7",
"    </a>",
"    ]. Single chamber ICDs implanted since 2002 had the longest battery life (mean 6.7 years).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Implantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current ICD lead systems utilizing between one and three leads are typically placed transvenously via the axillary, subclavian, or cephalic vein. Modern devices are small enough to be implanted in the pectoral region, either subcutaneously or sub-muscularly, similar to a pacemaker implantation. Compared to abdominal implantation, transvenous devices placed in the pectoral region are associated with fewer perioperative complications, shorter procedure time, shorter hospital stays, lower hospitalization costs, and lower total costs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Although implantation on the left side is preferred, a right sided implant can be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ICD PROGRAMMING AND THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As ICD technology has evolved, the number and variety of available programming and therapeutic options has dramatically increased. Contemporary ICDs have a variety of flexible programming and therapeutic options:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arrhythmia discrimination &ndash; The ability to distinguish arrhythmias requiring ICD therapy from other heart rhythms is crucial to appropriate ICD function. ICDs can be programmed to assess heart rate, atrioventricular dissociation, interval stability, QRS templates, and other parameters to help identify ventricular tachyarrhythmias requiring therapy. (See",
"      <a class=\"local\" href=\"#H27332059\">",
"       'Supraventricular tachyarrhythmias (including sinus tachycardia and atrial fibrillation) discrimination'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Multiple available therapies - ICDs are capable of treating ventricular arrhythmias with antitachycardia pacing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      shock. These therapies have parameters that can be varied and adjusted (eg, the rate and duration of antitachycardia pacing cycles and the delivered energy for cardioversion and defibrillation). These therapies are discussed in detail below. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Antitachycardia pacing'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H17\">",
"       'Cardioversion'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H18\">",
"       'Defibrillation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Multiple zones - ICDs can be programmed to provide different therapies to tachyarrhythmias in up to three heart rate zones. The rationale for this approach is that relatively slow ventricular arrhythmias (eg, ventricular tachycardia with a heart rate &lt;180",
"      <span class=\"nowrap\">",
"       beats/min)",
"      </span>",
"      often do not lead to loss of consciousness or other unstable symptoms for at least several minutes. Additionally, slower ventricular tachycardia (VT) can often be terminated with antitachycardia pacing or low-energy cardioversion, therapies that can be delivered quickly and with little or no pain. In contrast, faster tachycardias (eg, heart rate &gt;200",
"      <span class=\"nowrap\">",
"       beats/min)",
"      </span>",
"      are more likely to be unstable and poorly tolerated; they can require high-energy defibrillation, and can become increasingly difficult to terminate if definitive therapy is delayed. Thus, the preferred approach for such tachycardias is immediate high-energy defibrillation.",
"     </li>",
"     <li>",
"      Sequential therapies - In each therapy zone, a sequence of up to five or six therapies (bursts of antitachycardia pacing, cardioversion, or defibrillation) can be delivered. After each therapy, the device reevaluates the rhythm, and if the tachyarrhythmia persists, the next therapy is delivered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27332059\">",
"    <span class=\"h2\">",
"     Supraventricular tachyarrhythmias (including sinus tachycardia and atrial fibrillation) discrimination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supraventricular tachyarrhythmias (SVTs) are common in patients with ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. If the ICD interprets an SVT incorrectly, the patient may experience inappropriate shocks, which occur in 20 to 25 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. In general, ventricular tachyarrhythmia detection algorithms are based upon programmed rate cutoffs (ie, the device categorizes any detected heart rate above a programmed threshold as ventricular tachycardia [VT] or ventricular fibrillation [VF]). To improve discrimination between",
"    <span class=\"nowrap\">",
"     VF/VT",
"    </span>",
"    and supraventricular tachycardias, some devices incorporate additional features into discrimination algorithms. However, it is not clear that any specific algorithm reduces inappropriate shocks.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial rate versus ventricular rate &ndash; In dual chamber devices, information from the atrial electrode may help differentiate ventricular tachycardia (VT) from atrial tachyarrhythmias [",
"      <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/5,13-15\">",
"       5,13-15",
"      </a>",
"      ]. The primary discriminator is heart rate; if the atrial rate is greater than the ventricular rate, the arrhythmia is almost certainly SVT, usually atrial fibrillation or atrial flutter.",
"     </li>",
"     <li>",
"      Atrioventricular dissociation &ndash; Identification of different and distinct rhythms in the atrium and the ventricle, particularly when the ventricular rate exceeds the atrial rate, is consistent with atrioventricular dissociation seen with VT.",
"     </li>",
"     <li>",
"      QRS templates &ndash; Some devices record templates of the ventricular electrogram during sinus rhythm. During a tachyarrhythmia, the device compares the electrograms during the tachycardia to the baseline. Deviations in shape, duration, and polarity all increase the likelihood that the device will categorize the tachycardia as VT or VF.",
"     </li>",
"     <li>",
"      An interval stability criterion detects irregularity in cycle length and can distinguish atrial fibrillation from ventricular tachycardia (this approach may be less effective when the patient is treated with a class IC antiarrhythmic drug) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An onset criterion monitors the cycle length for the sudden or abrupt onset of a high ventricular rate (indicative of a VT) rather than a gradually increasing heart rate (as might be seen in exercise-induced sinus tachycardia).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these discrimination features is designed to help to prevent an SVT from being erroneously categorized as VT or VF, and therefore they reduce the likelihood of inappropriate shocks. However, none of these discriminators is 100 percent specific for SVT. For persistent tachycardias, these discriminators can be programmed to \"time-out\" so that the ICD eventually treats the arrhythmia as",
"    <span class=\"nowrap\">",
"     VT/VF.",
"    </span>",
"   </p>",
"   <p>",
"    In addition to discrimination criteria, most contemporary ICDs have a \"second look\" feature designed to help prevent or limit inappropriate shocks. Once the criteria for delivering a shock are met, the capacitors charge. This takes several seconds. Following charging, the device reevaluates the heart rhythm to confirm that the tachycardia persists and has not spontaneously terminated. It is expected that if the tachycardia has resolved, no shock will be delivered for noncommitted devices.",
"   </p>",
"   <p>",
"    Dual-chamber ICDs can be programmed for mode switching to prevent inappropriate tracking of atrial arrhythmias. In addition, some devices can deliver therapy for atrial tachyarrhythmias such as pace termination of atrial flutter or shock therapy for atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. However, patient acceptance has been limited for device-based shock therapy for atrial fibrillation. Most patients experience discomfort even at low energy output.",
"   </p>",
"   <p>",
"    Therapeutic alternatives for patients who continue to have frequent inappropriate shocks for atrial tachyarrhythmias include antiarrhythmic drugs and catheter ablation. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Antiarrhythmic drugs'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link&amp;anchor=H7#H7\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Adjunctive therapy in patients with an ICD'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H28\">",
"     'Catheter ablation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Antitachycardia pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular tachycardia (VT), particularly reentrant VT associated with scar from a prior myocardial infarction, can sometimes be terminated by pacing the ventricle at a rate slightly faster than the tachycardia. When a paced impulse enters the reentrant circuit during a tachycardia, it can depolarize a segment of the circuit, leaving that segment refractory when the reentrant wave returns, thus terminating the tachycardia.",
"   </p>",
"   <p>",
"    Antitachycardia pacing, or overdrive pacing, refers to the delivery of short bursts (eg, eight beats) of rapid ventricular pacing to terminate VT. Although a variety of algorithms exist, antitachycardia pacing is usually programmed to be delivered at a rate that is slightly faster (eg, at a cycle length 10 to 12 percent shorter) than the rate of the detected tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. In several observational and prospectively randomized studies, as many as 95 percent of episodes of spontaneous VT were successfully terminated with antitachycardia pacing, and this approach is comparable in efficacy to low-energy cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/22,24-27\">",
"     22,24-27",
"    </a>",
"    ]. Despite this success rate, antitachycardia pacing appears to be less successful in patients with monomorphic VT and variable morphologies or cycles lengths. In a cohort of 52 patients experiencing 833 episodes of monomorphic VT over a mean follow up of 30 months, antitachycardia pacing terminated significantly more monomorphic VT episodes in patients with one VT morphology compared to those with multiple VT morphologies (95 percent versus 85 and 70 percent with 2 or &ge;3 morphologies, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One concern with antitachycardia pacing is that rapid pacing can cause VT to degenerate into ventricular fibrillation (VF). For this reason, all ICDs also have high-energy defibrillation, which can be used after antitachycardia pacing as a backup therapy, if necessary. However, this theoretical problem associated with antitachycardia pacing appears to be uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/17,23,29-32\">",
"     17,23,29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although commonly used for slower VT (eg, heart rate &lt;180",
"    <span class=\"nowrap\">",
"     beats/min),",
"    </span>",
"    antitachycardia pacing can also be useful for more rapid VT. In the PainFREE Rx II trial, 634 patients with ICDs were randomly assigned to empirical antitachycardia pacing or shock for initial therapy of spontaneous rapid VT (188 to 250 bpm) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/30\">",
"     30",
"    </a>",
"    ]. In a mean of 11 months of follow-up, 431 episodes of rapid VT occurred in 98 patients. Pacing was successful in terminating 229 of 284 such episodes in the antitachycardia pacing arm (81 percent). The incidence of VT acceleration, syncope, and sudden death was the same in the antitachycardia pacing and shock arms (seven versus five episodes). The median duration of arrhythmia was also similar in the two arms (10.0 versus 9.7 minutes).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cardioversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A shock that is synchronized to be delivered at the peak of the R wave is referred to as cardioversion. Because ventricular tachycardia (VT) is an organized electrical rhythm, the delivery of an electrical shock during the vulnerable period of repolarization can cause VT to degenerate into ventricular fibrillation (VF). Synchronized cardioversion prevents shock delivery during the vulnerable period.",
"   </p>",
"   <p>",
"    Although ICDs can be programmed to deliver synchronized shocks at a range of energies up to the maximum output of the device (usually 30 to 35 joules), synchronized cardioversion can often terminate VT with relatively low energy (eg, 10 joules or less). \"Low energy cardioversion\" is defined as a synchronized shock of less than two joules. Backup defibrillation capability is essential, since low-energy cardioversion can accelerate the rate of VT. Low-energy cardioversion is comparable in efficacy to antitachycardia pacing for termination of VT [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Because antitachycardia pacing is painless, it is generally used first, followed by cardioversion, if necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Antitachycardia pacing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Defibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An unsynchronized shock (ie, a shock delivered randomly during the cardiac cycle) is referred to as defibrillation. Clinicians can program ICDs to deliver unsynchronized shocks for very rapid ventricular arrhythmias (eg, heart rate greater than 200",
"    <span class=\"nowrap\">",
"     beats/min).",
"    </span>",
"    Such rapid ventricular arrhythmias are usually ventricular fibrillation (VF), although very rapid ventricular tachycardia (VT) can have a heart rate greater than 200",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"    Because VF is not an organized rhythm, synchronized cardioversion is neither possible nor necessary. Similarly, it can be difficult to synchronize with very rapid VTs, and such rapid rhythms are unlikely to be hemodynamically tolerated. Thus, for very rapid VT, the potential benefit of synchronized cardioversion (avoidance of degeneration to VF) is less important than the delivery of immediate therapy.",
"   </p>",
"   <p>",
"    Defibrillation can be delivered across a range of energies. Initial shocks are often programmed for lower energies in order to reduce capacitor charge time and expedite therapy (although all shocks should be at least 10 joules above the defibrillation threshold). Subsequent shocks are usually delivered at higher energies, often at the maximum output of the ICD (eg, 30 to 35 joules), in order to optimize efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Defibrillation threshold",
"    </span>",
"    &nbsp;&mdash;&nbsp;The defibrillation threshold (DFT) refers to the minimum energy required to defibrillate a patient through the ICD. The DFT is usually determined at the end of the implantation procedure. Many centers also test DFTs routinely during follow-up. The method, timing, and necessity for DFT testing are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39672?source=see_link&amp;anchor=H5#H5\">",
"     \"Implantable cardioverter-defibrillators: Patient follow-up\", section on 'Defibrillation function testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=see_link&amp;anchor=H23#H23\">",
"     \"Implantable cardioverter-defibrillators: Complications\", section on 'Increased defibrillation threshold'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2161774\">",
"    <span class=\"h3\">",
"     Atrial defibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;While implantable atrial defibrillators (IADs) which are capable of detecting and terminating atrial fibrillation (AF) can be an effective means of restoring sinus rhythm, these devices were never approved as stand-alone devices, and they remain infrequently used as part of an ICD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/34\">",
"     34",
"    </a>",
"    ]. The principle advantage of IAD is its ability to restore sinus rhythm promptly in most episodes of AF without the need for hospitalization or clinician intervention. Patients who might benefit from an IAD include those with episodes of AF lasting &ge;24 hours or requiring pharmacologic or electrical cardioversion before this time, those with persistent AF (&ge;7 days) that can be successfully cardioverted and who experience late recurrences requiring repeated external cardioversion and in whom rate control and anticoagulation are not a desired alternative, and those in whom restoration and maintenance of sinus rhythm is highly desirable.",
"   </p>",
"   <p>",
"    Antiarrhythmic drug therapy is desirable in most patients who receive an IAD to reduce the number of AF recurrences and the frequency of device intervention. The selection of an appropriate antiarrhythmic agent is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27332349\">",
"    <span class=\"h2\">",
"     Tiered therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tiered therapy refers to the combination of multiple therapies in multiple heart rate zones or \"tiers\". The flexibility of tiered therapy is valuable in a variety of clinical settings, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A patient with multiple arrhythmias of different rates and hemodynamic characteristics.",
"     </li>",
"     <li>",
"      Following the addition of antiarrhythmic drugs to a patient's regimen, as such drugs can alter the characteristics of ventricular arrhythmias.",
"     </li>",
"     <li>",
"      For a patient with an ICD placed for primary prevention of SCD. In such a patient, the nature and characteristics of a future ventricular arrhythmia is unknown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In each of these circumstances, tiered therapy offers reduced morbidity by treating slower arrhythmias with antitachycardia pacing, while maintaining the availability of high-energy defibrillation when necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Tailored versus empiric programming",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advantages of tiered therapy ICDs are countered by the increased complexity of device programming. Clinicians will often attempt to tailor therapies based upon the results of electrophysiologic study",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a patient's arrhythmia history. While this approach can be beneficial, the randomized EMPIRIC trial found that a standardized programming protocol using antitachycardia pacing and multiple therapy zones was at least as effective as patient-specific tailored programming (",
"    <a class=\"graphic graphic_table graphicRef65026 \" href=\"UTD.htm?25/26/26027\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9233111\">",
"    <span class=\"h2\">",
"     Optimal ICD programming",
"    </span>",
"    &nbsp;&mdash;&nbsp;For decades, the optimal ICD programming to deliver antitachycardia ICD therapies, either pacing or shocks, was thought to involve delivering therapy with the minimal possible delay and for any ventricular arrhythmia that is present and sustained until therapy delivery. However, the exact circumstances in which to institute therapy for a tachyarrhythmia in patients with an ICD were not known. The hemodynamic response to an arrhythmia can vary considerably depending on the ventricular rate as well as the underlying cardiac disease and other comorbidities. The impact of delivering early therapy for a potentially self-limiting ventricular tachyarrhythmia and for supraventricular tachyarrhythmias, including sinus tachycardia, on outcomes including mortality has been unknown. However, the delivery of frequent or inappropriate ICD shocks and even ATP can have a negative impact on the patient's quality of life.",
"   </p>",
"   <p>",
"    MADIT-RIT, a randomized trial of three different ICD programming and therapy strategies, assigned 1500 patients receiving an ICD for primary prevention to one of three programming strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      \"Conventional\" therapy programming &ndash; 2.5 second delay at rates of 170 to 199 beats per minute; 1 second delay at rates of 200 or more beats per minute.",
"     </li>",
"     <li>",
"      Delayed therapy programming &ndash; 60 second delay at rates of 170 to 199 beats per minute; 12 second delay at rates of 200 to 249 beats per minute; 2.5 second delay at rates of 250 or more beats per minute.",
"     </li>",
"     <li>",
"      High-rate therapy programming &ndash; No therapy at rates of 170 to 199 beats per minutes; 2.5 second delay at rates of 200 or more beats per minute.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients were followed for an average of 1.4 years, with the primary outcome being the time to first delivery of inappropriate therapy and two pre-specified secondary outcomes (all-cause mortality and first syncopal episode). While relatively few patients received appropriate ICD therapy (242 patients, or 16 percent, with 70 percent of appropriate therapies being ATP), the primary outcome occurred in 152 patients (11 percent). When compared to conventional programming:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inappropriate therapies were lower in both high-rate therapy (hazard ratio [HR] 0.21, 95% CI 0.13-0.34) and the delayed therapy (HR 0.24, 95% CI 0.15-0.40) groups.",
"     </li>",
"     <li>",
"      All-cause mortality was lower in the high-rate therapy group (HR 0.45, 95% CI 0.24-0.85), and there was a trend toward lower mortality in the delayed therapy group that was not statistically significant (HR 0.56, 95% CI 0.30-1.02).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients receiving an ICD for primary prevention, we recommend strategies that delay therapy or only institute therapy for very high heart rates, rather than a \"conventional\" ICD strategy that rapidly administers therapy with minimal delay. Between the two alternative strategies investigated in MADIT-RIT, we suggest using the high-rate therapy programming strategy. Settings that can be used for this preferred strategy are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Heart rate 170 to 199 beats per minute &ndash; No therapy with monitoring only",
"     </li>",
"     <li>",
"      Heart rate 200 beats per minute or greater &ndash; 2.5 second delay at rates prior to therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This approach, however, should not be routinely adopted for all patients with an ICD, as it has not been tested in patients with a prior history of hemodynamically significant ventricular tachyarrhythmias in whom an ICD has been placed for secondary prevention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ADDITIONAL CAPABILITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contemporary ICDs have a number of additional features, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recording and display of stored electrograms from tachyarrhythmia events. This can be very helpful for the detection of \"silent\" or asymptomatic arrhythmias where management of the patient is likely to change (eg, atrial fibrillation).",
"     </li>",
"     <li>",
"      Noninvasive, programmed stimulation that allows convenient electrophysiologic provocation of an arrhythmia to test the efficacy of an ICD for a given patient.",
"     </li>",
"     <li>",
"      Telemetry capabilities that permit easier troubleshooting when patients receive shocks.",
"     </li>",
"     <li>",
"      Remote monitoring capabilities via telephone or internet that allow clinicians to review ICD parameters and events without requiring the patient to come to the office or hospital.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cardiac pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;All contemporary ICDs are capable of pacing. Many patients with an ICD have a conventional indication for cardiac pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/37\">",
"     37",
"    </a>",
"    ]. With rare exceptions, patients have only one device. Separate ICDs and pacemakers can produce device-to-device interactions because of the close proximity of the pacing and defibrillation leads, resulting in inappropriate shocks, and underdetection of VF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. In order to avoid such interactions, when a patient with a pacemaker develops an indication for ICD implantation, the pacemaker is usually removed and replaced with an ICD.",
"   </p>",
"   <p>",
"    In addition to the usual indications for pacing, pacing also protects against bradyarrhythmias that can follow a tachycardia or shock, and also against ventricular arrhythmias that are brady-dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/42\">",
"     42",
"    </a>",
"    ]. Because of the unique physiology following a ventricular tachyarrhythmia and device shock, ICDs allow for distinct post-shock pacing programming (usually at higher outputs).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Cardiac resynchronization therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac resynchronization therapy (CRT), which utilizes biventricular pacing, is an effective treatment for symptomatic heart failure in some patients with left ventricular dyssynchrony. CRT is currently recommended in patients with advanced heart failure (usually NYHA class III or IV), severe systolic dysfunction (left ventricular ejection fraction &le;35 percent) and intraventricular conduction delay (QRS &gt;120 msec). Pacing of the left ventricle is most frequently achieved by transvenous insertion of an electrode into a cardiac vein via the coronary sinus. Surgical placement of an epicardial lead is also an option in patients following failed efforts at transvenous lead placement, or in patients undergoing cardiac surgery for another reason. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10823?source=see_link\">",
"     \"Rationale for and mechanisms of benefit of cardiac resynchronization therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11545?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Implantation and other considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Improvement in heart failure can reduce the frequency of ventricular arrhythmias, raising the possibility that biventricular pacing may have an adjunctive role with an ICD by reducing the need for ICD therapy. Although an initial series of 32 patients found such an effect [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/43\">",
"     43",
"    </a>",
"    ], this benefit was not confirmed in the much larger MIRACLE ICD trial of 369 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/44\">",
"     44",
"    </a>",
"    ]. Although the addition of biventricular pacing to ICD therapy was associated with significant improvements in symptoms and quality of life, there was no reduction in the number of appropriate or inappropriate shocks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10823?source=see_link\">",
"     \"Rationale for and mechanisms of benefit of cardiac resynchronization therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Minimizing right ventricular pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the possible benefit of biventricular pacing in patients with heart failure and intraventricular conduction delay, where maximum pacing improves resynchronization, prolonged unopposed right ventricular (RV) pacing is harmful. Unnecessary RV pacing has been associated with an increased incidence of adverse outcomes, including death, hospitalization for heart failure, and atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. The presumed mechanism is that RV pacing causes ventricular dyssynchrony, simulating the effects of left bundle branch block. The loss of ventricular synchrony with pacing may worsen left ventricular (LV) systolic function, whereas restoration of ventricular synchrony has been shown to improve LV systolic function [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. For this reason, both ICDs and permanent pacemakers are now programmed to minimize right ventricular pacing, whenever possible [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31510?source=see_link\">",
"     \"Overview of cardiac pacing in heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=see_link&amp;anchor=H13#H13\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\", section on 'Modes to minimize ventricular pacing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE THERAPY WITH ICD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiarrhythmic drugs and catheter ablation may play adjunctive roles in the management of patients treated with an ICD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Antiarrhythmic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of antiarrhythmic drugs in patients with an ICD is discussed in detail separately. Summarized briefly, there are three main indications for concomitant antiarrhythmic drug therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To reduce the frequency of ventricular arrhythmias in patients with frequent ICD shocks [",
"      <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/51\">",
"       51",
"      </a>",
"      ]. Patients with frequent shocks are more likely to become psychologically distressed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link&amp;anchor=H8#H8\">",
"       \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'Quality of life'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      To suppress other arrhythmias that cause symptoms or interfere with ICD function, resulting in \"inappropriate\" discharges. These arrhythmias include sinus tachycardia, atrial arrhythmias, especially atrial fibrillation, and nonsustained ventricular tachycardia (VT). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link&amp;anchor=H7#H7\">",
"       \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'Causes of ICD discharge'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      To reduce the rate of VT so that it is better tolerated hemodynamically and more amenable to pace-termination or low-energy cardioversion. Although antiarrhythmic drugs may be used for these reasons, more sophisticated programming features may allow the device to ignore clinically unimportant and non-life-threatening arrhythmias rather than delivering an unnecessary shock.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    is the most effective antiarrhythmic agent for the treatment of ventricular tachyarrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link&amp;anchor=H7#H7\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Adjunctive therapy in patients with an ICD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some antiarrhythmic drugs, in additional to their usual side effects, may have an adverse effect on defibrillation thresholds (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    may increase the defibrillation threshold) and, by slowing the tachycardia rate, may preclude its recognition by the device [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. These potential problems mandate reevaluation of tachycardia response and defibrillation thresholds whenever an antiarrhythmic drug that can affect device function is added, whenever an antiarrhythmic dose is changed, or when a condition supervenes that is likely to alter the pharmacokinetics or pharmacodynamics of a drug in use [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=see_link&amp;anchor=H23#H23\">",
"     \"Implantable cardioverter-defibrillators: Complications\", section on 'Increased defibrillation threshold'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Catheter ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to antiarrhythmic drug therapy in patients with frequent recurrences of ventricular tachycardia is radiofrequency ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. Ablation therapy is also a consideration for atrial arrhythmias (eg, atrial fibrillation, atrial flutter, atrioventricular nodal reentrant tachycardia), particularly if the atrial arrhythmia is refractory to medical therapy or results in \"inappropriate\" ICD shocks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Ablation as a treatment for both ventricular and atrial arrhythmias is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=see_link\">",
"     \"Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2629766\">",
"    <span class=\"h1\">",
"     REUSE OF EXPLANTED ICDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many ICD pulse generators have useful battery life remaining at the time of a patient's death or when the ICD is explanted due to infection or device upgrade. Because of concerns regarding the transmission of infectious disease from patient to patient, and because of the lack of data regarding device reliability when used in such a fashion, reuse of explanted ICDs has not been approved by any governing or regulatory body. However, due to the large numbers of patients in resource-limited settings who have indications for an ICD but are unable to afford the device, there is a potential for compassionate reuse of ICDs if sterility and reliability can be assured. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Indications for ICD therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    From a single-center cohort of 81 indigent patients with indications for an ICD who received 106 explanted ICD pulse generators (cleaned and sterilized using a protocol involving",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    , povidone-iodine, and ethylene oxide gas) with a projected battery life of three or more years, the following findings were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/60\">",
"     60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No infectious complications",
"     </li>",
"     <li>",
"      One lead dislodgement and one lead fracture",
"     </li>",
"     <li>",
"      Mean time to subsequent ICD replacement 1287 days",
"     </li>",
"     <li>",
"      Appropriate ICD therapy (shocks or antitachycardia pacing) in 64 out of 106 devices (60 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This preliminary report suggests the feasibility of reusing explanted ICD pulse generators that have been meticulously sterilized and have a reasonably long projected battery life. However, until additional studies confirm the safety and reliability of this process, and without guidance or approval from any governing or regulatory body, we do not recommend reusing explanted ICDs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     WEARABLE CARDIOVERTER-DEFIBRILLATOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients who are at risk for SCD do not meet established criteria for implantation of an ICD or may require only short-term protection (such as patients awaiting subsequent ICD insertion or cardiac transplantation). In such settings, a wearable cardioverter-defibrillator may be preferable to either ICD insertion or bystander resuscitation. The indications for use, efficacy, and limitations of the wearable cardioverter-defibrillator are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36088?source=see_link\">",
"     \"Wearable cardioverter-defibrillator\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21112589\">",
"    <span class=\"h1\">",
"     SUBCUTANEOUS ICD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonrandomized studies have evaluated the feasibility of an investigational entirely subcutaneous ICD system [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/61-65\">",
"     61-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 49 patients who received both a temporary subcutaneous ICD and a transvenous ICD, the subcutaneous device was as effective as a transvenous ICD although required higher energy for successful defibrillation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/61\">",
"       61",
"      </a>",
"      ]. Ventricular fibrillation induced at the time of implantation was successfully converted in 98 percent of patients with a permanent subcutaneous ICD. Adverse events included two pocket infections and four lead revisions. Over 10 months of follow-up, the device successfully detected and treated all 12 episodes of spontaneous, sustained ventricular tachycardia.",
"     </li>",
"     <li>",
"      Data from the IDE trial have been presented to the FDA; an executive summary is available",
"      <a class=\"external\" href=\"file://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM301228.pdf\">",
"       online",
"      </a>",
"      . Three hundred thirty patients were enrolled and 314 implanted with the S-ICD, with both the primary efficacy (induced ventricular fibrillation conversion rate) and safety (180-day complication free rate) endpoints being met [",
"      <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/66\">",
"       66",
"      </a>",
"      ]. However, the data have not yet been published in a peer reviewed format.",
"     </li>",
"     <li>",
"      Data from the Effortless ICD Registry, an observational study of European patients who have received the S-ICD since its approval, were also presented at the 2012 Cardiostim conference in France [",
"      <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/63\">",
"       63",
"      </a>",
"      ]. Encouragingly, only approximately 7 percent of patients received an inappropriate shock, a rate which is about half that seen in the IDE study.",
"     </li>",
"     <li>",
"      Among a cohort of 118 Dutch patients who received the S-ICD at one of four centers and had at least 12 months of follow-up (mean 18 months), eight patients (7 percent) received 45 appropriate shocks with a 98 percent first shock success rate for termination of the ventricular arrhythmia [",
"      <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/64\">",
"       64",
"      </a>",
"      ]. Fifteen patients (13 percent) received a total of 33 inappropriate shocks during follow-up, while 16 patients (14 percent) experienced complications, with infection (seven patients) being the most common complication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Though the S-ICD lacks some of the features in standard transvenous ICDs (no antitachycardia pacing, bradycardia pacing limited to transient post-shock pacing only), the absence of a transvenous lead obviates a number of potential device complications (eg, venous occlusion, infection requiring laser extraction, etc) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/50/24362/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/60/38850?source=see_link\">",
"       \"Patient information: Implantable cardioverter-defibrillators (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=see_link\">",
"       \"Patient information: Sudden cardiac arrest (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=see_link\">",
"       \"Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179461098\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Success with external defibrillation of ventricular tachyarrhythmias led to development of an implantable cardioverter-defibrillator (ICD), first used in a human in 1980. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main indications for use of an ICD relate to secondary prevention in patients with prior ventricular tachycardia (VT), ventricular fibrillation (VF), or resuscitated sudden cardiac death (SCD) as well as primary prevention in patients at increased risk of",
"      <span class=\"nowrap\">",
"       VT/VF.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications for ICD therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'When ICD therapy is not indicated'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Modern ICD systems consist of three main components:",
"      <span class=\"nowrap\">",
"       pacing/sensing",
"      </span>",
"      electrodes, defibrillation electrodes (generally combined on one transvenous lead with the",
"      <span class=\"nowrap\">",
"       pacing/sensing",
"      </span>",
"      electrodes), and the pulse generator. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Elements of the ICD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All contemporary ICDs are capable of conventional cardiac pacing, and many ICD patients have a concurrent indication for cardiac pacing. Efforts should be made, however, to minimize unnecessary and unopposed right ventricular pacing, as this leads to an increased risk of adverse outcomes including death and heart failure. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Cardiac pacing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Contemporary ICDs have a variety of flexible programming options for both arrhythmia detection and treatment. Most ICDs utilize tiered therapies, supraventricular tachycardia (SVT) discrimination, antitachycardia pacing and low-energy cardioversion, in an effort to minimize delivery of high-voltage defibrillatory shocks, which are more uncomfortable for patients. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'ICD programming and therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SVT is common in patients with ventricular arrhythmias and can result in \"inappropriate\" ICD shocks if not recognized. Contemporary ICDs contain a variety of features designed to discriminate ventricular tachyarrhythmias from SVT. (See",
"      <a class=\"local\" href=\"#H27332059\">",
"       'Supraventricular tachyarrhythmias (including sinus tachycardia and atrial fibrillation) discrimination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antitachycardia pacing refers to the delivery of short bursts of rapid ventricular pacing to terminate VT. Up to 95 percent of spontaneous VT episodes are successfully terminated with antitachycardia pacing, comparable to the efficacy of low-energy cardioversion. In most patients, antitachycardia pacing is programmed as the first-line therapy for VT. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Antitachycardia pacing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because VF is not an organized rhythm, neither antitachycardia pacing nor low-energy cardioversion will be effective as treatment, thereby necessitating high-energy defibrillation. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Defibrillation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients receiving an ICD for primary prevention, we recommend strategies that delay therapy or only institute therapy for very high heart rates, rather than a \"conventional\" ICD strategy that rapidly administers therapy with minimal delay (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Between the two alternative strategies investigated in MADIT-RIT, we suggest using the high rate therapy programming strategy rather than the delayed therapy programming strategy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Settings that can be used for this preferred strategy are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Heart rate 170 to 199 beats per minute &ndash; No therapy with monitoring only",
"     </li>",
"     <li>",
"      Heart rate 200 beats per minute or greater &ndash; 2.5 second delay at rates prior to therapy",
"      <br/>",
"      <br/>",
"      This approach, however, should not be routinely adopted for all patients with an ICD, as it has not been tested in patients with a prior history of hemodynamically significant ventricular tachyarrhythmias in whom an ICD has been placed for secondary prevention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adjunctive therapy with either antiarrhythmic medication or catheter ablation is important in the management of patients treated with an ICD, particularly as an effort to prevent recurrent ICD shocks in patients who have received multiple ICD shocks. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Adjunctive therapy with ICD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/1\">",
"      Mirowski M, Mower MM, Staewen WS, et al. Standby automatic defibrillator. An approach to prevention of sudden coronary death. Arch Intern Med 1970; 126:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/2\">",
"      Mirowski M, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 1980; 303:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/3\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/4\">",
"      DiMarco JP. Implantable cardioverter-defibrillators. N Engl J Med 2003; 349:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/5\">",
"      Israel CW, Gr&ouml;nefeld G, Iscolo N, et al. Discrimination between ventricular and supraventricular tachycardia by dual chamber cardioverter defibrillators: importance of the atrial sensing function. Pacing Clin Electrophysiol 2001; 24:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/6\">",
"      Fenelon G, Huvelle E, Brugada P. Initial clinical experience with a new small sized third-generation implantable cardioverter defibrillator: results of a multicenter study. European Ventak Mini Investigator Group. Pacing Clin Electrophysiol 1997; 20:2967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/7\">",
"      Thijssen J, Borleffs CJ, van Rees JB, et al. Implantable cardioverter-defibrillator longevity under clinical circumstances: an analysis according to device type, generation, and manufacturer. Heart Rhythm 2012; 9:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/8\">",
"      Anvari A, Stix G, Grabenw&ouml;ger M, et al. Comparison of three cardioverter defibrillator implantation techniques: initial results with transvenous pectoral implantation. Pacing Clin Electrophysiol 1996; 19:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/9\">",
"      Cardinal DS, Connelly DT, Steinhaus DM, et al. Cost savings with nonthoracotomy implantable cardioverter-defibrillators. Am J Cardiol 1996; 78:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/10\">",
"      Pacifico A, Johnson JW, Stanton MS, et al. Comparison of results in two implantable defibrillators. Jewel 7219D Investigators. Am J Cardiol 1998; 82:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/11\">",
"      Flaker GC, Tummala R, Wilson J. Comparison of right- and left-sided pectoral implantation parameters with the Jewel active can cardiodefibrillator. The World Wide Jewel Investigators. Pacing Clin Electrophysiol 1998; 21:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/12\">",
"      Gold MR, Shih HT, Herre J, et al. Comparison of defibrillation efficacy and survival associated with right versus left pectoral placement for implantable defibrillators. Am J Cardiol 2007; 100:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/13\">",
"      Swerdlow CD, Schsls W, Dijkman B, et al. Detection of atrial fibrillation and flutter by a dual-chamber implantable cardioverter-defibrillator. For the Worldwide Jewel AF Investigators. Circulation 2000; 101:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/14\">",
"      Adler SW 2nd, Wolpert C, Warman EN, et al. Efficacy of pacing therapies for treating atrial tachyarrhythmias in patients with ventricular arrhythmias receiving a dual-chamber implantable cardioverter defibrillator. Circulation 2001; 104:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/15\">",
"      Friedman PA, Dijkman B, Warman EN, et al. Atrial therapies reduce atrial arrhythmia burden in defibrillator patients. Circulation 2001; 104:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/16\">",
"      Wood MA, Stambler BS, Damiano RJ, et al. Lessons learned from data logging in a multicenter clinical trial using a late-generation implantable cardioverter-defibrillator. The Guardian ATP 4210 Multicenter Investigators Group. J Am Coll Cardiol 1994; 24:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/17\">",
"      Nunain SO, Roelke M, Trouton T, et al. Limitations and late complications of third-generation automatic cardioverter-defibrillators. Circulation 1995; 91:2204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/18\">",
"      Grimm W, Flores BF, Marchlinski FE. Electrocardiographically documented unnecessary, spontaneous shocks in 241 patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol 1992; 15:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/19\">",
"      Klein RC, Raitt MH, Wilkoff BL, et al. Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Cardiovasc Electrophysiol 2003; 14:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/20\">",
"      Swerdlow CD, Chen PS, Kass RM, et al. Discrimination of ventricular tachycardia from sinus tachycardia and atrial fibrillation in a tiered-therapy cardioverter-defibrillator. J Am Coll Cardiol 1994; 23:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/21\">",
"      Le Franc P, Ku T, Vinet A, et al. Underdetection of ventricular tachycardia using a 40 ms stability criterion: effect of antiarrhythmic therapy. Pacing Clin Electrophysiol 1997; 20:2882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/22\">",
"      Schaumann A, von zur M&uuml;hlen F, Herse B, et al. Empirical versus tested antitachycardia pacing in implantable cardioverter defibrillators: a prospective study including 200 patients. Circulation 1998; 97:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/23\">",
"      Trappe HJ, Klein H, Kielblock B. Role of antitachycardia pacing in patients with third generation cardioverter defibrillators. Pacing Clin Electrophysiol 1994; 17:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/24\">",
"      Saksena S, Chandran P, Shah Y, et al. Comparative efficacy of transvenous cardioversion and pacing in patients with sustained ventricular tachycardia: a prospective, randomized, crossover study. Circulation 1985; 72:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/25\">",
"      Bardy GH, Poole JE, Kudenchuk PJ, et al. A prospective randomized repeat-crossover comparison of antitachycardia pacing with low-energy cardioversion. Circulation 1993; 87:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/26\">",
"      Clinical outcome of patients with malignant ventricular tachyarrhythmias and a multiprogrammable implantable cardioverter-defibrillator implanted with or without thoracotomy: an international multicenter study. PCD Investigator Group. J Am Coll Cardiol 1994; 23:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/27\">",
"      Sullivan RM, Russo AM, Berg KC, et al. Arrhythmia rate distribution and tachyarrhythmia therapy in an ICD population: results from the INTRINSIC RV trial. Heart Rhythm 2012; 9:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/28\">",
"      Clemens M, Nagy-Bal&oacute; E, Herczku C, et al. Long-term arrhythmia variability after monomorphic ventricular tachycardia in patients with an implantable cardioverter defibrillator. Pacing Clin Electrophysiol 2011; 34:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/29\">",
"      Nasir N Jr, Pacifico A, Doyle TK, et al. Spontaneous ventricular tachycardia treated by antitachycardia pacing. Cadence Investigators. Am J Cardiol 1997; 79:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/30\">",
"      Wathen MS, DeGroot PJ, Sweeney MO, et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation 2004; 110:2591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/31\">",
"      Wathen MS, Sweeney MO, DeGroot PJ, et al. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation 2001; 104:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/32\">",
"      Pinski SL, Fahy GJ. The proarrhythmic potential of implantable cardioverter-defibrillators. Circulation 1995; 92:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/33\">",
"      Saksena S, Luceri R, Krol RB, et al. Endocardial pacing, cardioversion and defibrillation using a braided endocardial lead system. Am J Cardiol 1993; 71:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/34\">",
"      Mitchell AR, Spurrell PA, Boodhoo LE, Sulke N. Long-term care of the patient with the atrial defibrillator. Am Heart J 2004; 147:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/35\">",
"      Wilkoff BL, Ousdigian KT, Sterns LD, et al. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial. J Am Coll Cardiol 2006; 48:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/36\">",
"      Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012; 367:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/37\">",
"      Best PJ, Hayes DL, Stanton MS. The potential usage of dual chamber pacing in patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol 1999; 22:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/38\">",
"      Calkins H, Brinker J, Veltri EP, et al. Clinical interactions between pacemakers and automatic implantable cardioverter-defibrillators. J Am Coll Cardiol 1990; 16:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/39\">",
"      Ellenbogen KA, Edel T, Moore S, et al. A prospective randomized-controlled trial of ventricular fibrillation detection time in a DDDR ventricular defibrillator. Ventak AV II DR Study Investigators. Pacing Clin Electrophysiol 2000; 23:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/40\">",
"      Glikson M, Trusty JM, Grice SK, et al. A stepwise testing protocol for modern implantable cardioverter-defibrillator systems to prevent pacemaker-implantable cardioverter-defibrillator interactions. Am J Cardiol 1999; 83:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/41\">",
"      Mattke S, Markewitz A, M&uuml;ller D, et al. The combined transvenous implantation of cardioverter defibrillators and permanent pacemakers. Pacing Clin Electrophysiol 1997; 20:2775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/42\">",
"      Fisher JD, Teichman SL, Ferrick A, et al. Antiarrhythmic effects of VVI pacing at physiologic rates: a crossover controlled evaluation. Pacing Clin Electrophysiol 1987; 10:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/43\">",
"      Higgins SL, Yong P, Sheck D, et al. Biventricular pacing diminishes the need for implantable cardioverter defibrillator therapy. Ventak CHF Investigators. J Am Coll Cardiol 2000; 36:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/44\">",
"      Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003; 289:2685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/45\">",
"      Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 2002; 288:3115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/46\">",
"      Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation 2003; 107:2932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/47\">",
"      Yu CM, Chan JY, Zhang Q, et al. Biventricular pacing in patients with bradycardia and normal ejection fraction. N Engl J Med 2009; 361:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/48\">",
"      Fr&ouml;hlich G, Steffel J, H&uuml;rlimann D, et al. Upgrading to resynchronization therapy after chronic right ventricular pacing improves left ventricular remodelling. Eur Heart J 2010; 31:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/49\">",
"      Murakami Y, Tsuboi N, Inden Y, et al. Difference in percentage of ventricular pacing between two algorithms for minimizing ventricular pacing: results of the IDEAL RVP (Identify the Best Algorithm for Reducing Unnecessary Right Ventricular Pacing) study. Europace 2010; 12:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/50\">",
"      Olshansky B, Day JD, Moore S, et al. Is dual-chamber programming inferior to single-chamber programming in an implantable cardioverter-defibrillator? Results of the INTRINSIC RV (Inhibition of Unnecessary RV Pacing With AVSH in ICDs) study. Circulation 2007; 115:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/51\">",
"      Steinberg JS, Martins J, Sadanandan S, et al. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. Am Heart J 2001; 142:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/52\">",
"      Page RL. Effects of antiarrhythmic medication on implantable cardioverter-defibrillator function. Am J Cardiol 2000; 85:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/53\">",
"      Goldschlager N, Epstein A, Friedman P, et al. Environmental and drug effects on patients with pacemakers and implantable cardioverter/defibrillators: a practical guide to patient treatment. Arch Intern Med 2001; 161:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/54\">",
"      Strickberger SA, Man KC, Daoud EG, et al. A prospective evaluation of catheter ablation of ventricular tachycardia as adjuvant therapy in patients with coronary artery disease and an implantable cardioverter-defibrillator. Circulation 1997; 96:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/55\">",
"      Sra J, Bhatia A, Dhala A, et al. Electroanatomically guided catheter ablation of ventricular tachycardias causing multiple defibrillator shocks. Pacing Clin Electrophysiol 2001; 24:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/56\">",
"      O'Callaghan PA, Poloniecki J, Sosa-Suarez G, et al. Long-term clinical outcome of patients with prior myocardial infarction after palliative radiofrequency catheter ablation for frequent ventricular tachycardia. Am J Cardiol 2001; 87:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/57\">",
"      Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 2007; 357:2657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/58\">",
"      Shanmugam KT, Chan I, Morandi C. Regulation of nitrogen fixation. Nitrogenase-derepressed mutants of Klebsiella pneumoniae. Biochim Biophys Acta 1975; 408:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/59\">",
"      Butler J, Jayson GG, Swallow AJ. The reaction between the superoxide anion radical and cytochrome c. Biochim Biophys Acta 1975; 408:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/60\">",
"      Pavri BB, Lokhandwala Y, Kulkarni GV, et al. Reuse of explanted, resterilized implantable cardioverter-defibrillators: a cohort study. Ann Intern Med 2012; 157:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/61\">",
"      Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010; 363:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/62\">",
"      Jarman JW, Lascelles K, Wong T, et al. Clinical experience of entirely subcutaneous implantable cardioverter-defibrillators in children and adults: cause for caution. Eur Heart J 2012; 33:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/63\">",
"      Lambiase PD, Theuns DAMJ, Neuzil P, et al. International experience with a subcutaneous ICD; preliminary results of the EFFORTLESS S-ICD registry. Europace 2012; 14:i36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/64\">",
"      Olde Nordkamp LR, Dabiri Abkenari L, Boersma LV, et al. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. J Am Coll Cardiol 2012; 60:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/65\">",
"      K&ouml;be J, Reinke F, Meyer C, et al. Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter-defibrillators: a multicenter case-control study. Heart Rhythm 2013; 10:29.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM301228.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/50/24362/abstract/67\">",
"      Rowley CP, Gold MR. Subcutaneous implantable cardioverter defibrillator. Circ Arrhythm Electrophysiol 2012; 5:587.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 921 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-9F69235DB9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_50_24362=[""].join("\n");
var outline_f23_50_24362=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H179461098\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SUMMARY OF INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Indications for ICD therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1316894748\">",
"      - Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1316894755\">",
"      - Primary prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      When ICD therapy is not indicated",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ELEMENTS OF THE ICD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pace/sense electrodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Defibrillation electrodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pulse generator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Implantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ICD PROGRAMMING AND THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27332059\">",
"      Supraventricular tachyarrhythmias (including sinus tachycardia and atrial fibrillation) discrimination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Antitachycardia pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cardioversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Defibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Defibrillation threshold",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2161774\">",
"      - Atrial defibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27332349\">",
"      Tiered therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Tailored versus empiric programming",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9233111\">",
"      Optimal ICD programming",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ADDITIONAL CAPABILITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Cardiac resynchronization therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Minimizing right ventricular pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ADJUNCTIVE THERAPY WITH ICD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Catheter ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2629766\">",
"      REUSE OF EXPLANTED ICDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      WEARABLE CARDIOVERTER-DEFIBRILLATOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21112589\">",
"      SUBCUTANEOUS ICD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179461098\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/921\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/921|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/53/41813\" title=\"diagnostic image 1\">",
"      ICD lead systems Chest film",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/921|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/23/23925\" title=\"figure 1\">",
"      Transvenous ICD lead systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/921|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/26/26027\" title=\"table 2\">",
"      EMPIRIC arm VT VF settings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11545?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Implantation and other considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15304?source=related_link\">",
"      Catheter ablation for AV nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=related_link\">",
"      Catheter ablation for ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/23/376?source=related_link\">",
"      Electrical storm and incessant ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30599?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=related_link\">",
"      Implantable cardioverter-defibrillators: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39672?source=related_link\">",
"      Implantable cardioverter-defibrillators: Patient follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=related_link\">",
"      Indications and contraindications for cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28855?source=related_link\">",
"      Management of the patient with syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1849?source=related_link\">",
"      Modes of cardiac pacing: Nomenclature and selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=related_link\">",
"      Monomorphic ventricular tachycardia in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30041?source=related_link\">",
"      Outcome of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31510?source=related_link\">",
"      Overview of cardiac pacing in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/60/38850?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=related_link\">",
"      Patient information: Sudden cardiac arrest (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=related_link\">",
"      Pharmacologic therapy in survivors of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=related_link\">",
"      Prognosis and management of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/36/10823?source=related_link\">",
"      Rationale for and mechanisms of benefit of cardiac resynchronization therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=related_link\">",
"      Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=related_link\">",
"      Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36088?source=related_link\">",
"      Wearable cardioverter-defibrillator",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_50_24363="Muscle characteristics myotonic dystrophy I and II";
var content_f23_50_24363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F75472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F75472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Muscle characteristics of myotonic dystrophy (DM), types I and II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Type of DM",
"      </td>",
"      <td class=\"subtitle1\">",
"       Muscle groups commonly affected",
"      </td>",
"      <td class=\"subtitle1\">",
"       Clinical myotonia (grip and percussion)*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Muscle pain&bull;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Respiratory muscle involvement&Delta;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dysphagia and dysarthria&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       DM I (Steinert's disease)",
"      </td>",
"      <td>",
"       Facial, neck, forearm, hand intrinsic, foot dorsiflexor",
"      </td>",
"      <td>",
"       Common and often pronounced",
"      </td>",
"      <td>",
"       Yes (Rarely a presenting complaint)",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       DM II (Proximal myotonic myopathy)",
"      </td>",
"      <td>",
"       Neck flexor, elbow extensor, finger flexor, hip flexor",
"      </td>",
"      <td>",
"       Mild or inobvious",
"      </td>",
"      <td>",
"       Yes (Often a presenting complaint)",
"      </td>",
"      <td>",
"       Uncommon",
"      </td>",
"      <td>",
"       Uncommon",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Electrical myotonia is found in both disorders.",
"     <br>",
"      &bull; Pain is generally not correlated with myotonia.",
"      <br>",
"       &Delta; Important contributors to pneumonia and respiratory failure.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_50_24363=[""].join("\n");
var outline_f23_50_24363=null;
var title_f23_50_24364="Common causes of syncope";
var content_f23_50_24364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common causes of syncope",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Noncardiovascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Reflex mechanisms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vasovagal and vasodepressor syncope (neurocardiogenic syncope)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Micturition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Deglutition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cough",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Orthostatic hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dysautonomias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fluid depletion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Illness, bedrest, deconditioning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Drugs - antidepressants, sympathetic blockers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Psychogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hysterical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Panic disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anxiety disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Undiagnosed seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Improperly diagnosed syncope - confusional states, eg, due to hypoglycemia, stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug-induced loss of consciousness (consider alcohol, illicit drugs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiovascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Arrhythmic causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        AV block with bradycardia (structural changes, drugs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sinus pauses/bradycardia (vagal causes, sick sinus syndrome, negative chronotropic drugs such as beta blockers and calcium channel blockers)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ventricular tachycardia due to structural heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Nonarrhythmic causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypertrophic cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Aortic stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Syncope of unknown origin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        About 50 percent of patients presenting to the hospital",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_50_24364=[""].join("\n");
var outline_f23_50_24364=null;
var title_f23_50_24365="Malignant hyperthermia rapid response";
var content_f23_50_24365=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Malignant hyperthermia rapid response",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Clinical presentation and signs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Increasing end-tidal carbon dioxide",
"       </strong>",
"       : Mixed respiratory/metabolic acidosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Masseter muscle spasm with succinylcholine administration",
"       </strong>",
"       : Early sign of MH in many patients",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Rigidity",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Tachypnea/tachycardia",
"       </strong>",
"       : Nonspecific",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Unexpected cardiac arrest in a young patient",
"       </strong>",
"       : Presume hyperkalemia and treat (see below); may be due to an occult myopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Hyperthermia",
"       </strong>",
"       : May be late sign",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Myoglobinuria",
"       </strong>",
"       : Brown urine, hemoglobin on dipstick without RBCs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Acute treatment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Call for help",
"       </strong>",
"       : Call for MH crash cart; notify the surgeon; complete surgical procedure as soon as feasible; call",
"       <span class=\"red\">",
"        MH Hotline: 1-800-644-9737",
"       </span>",
"       (US); outside US: 1-315-464-7079",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Initiate support",
"       </strong>",
"       : Discontinue inhalational agents and succinylcholine; hyperventilate with 100% oxygen; use non-triggering agents for the remainder of the procedure; intubate with endotracheal tube",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <span class=\"red\">",
"        <strong>",
"         Give dantrolene",
"        </strong>",
"        : Add 60 mL sterile preservative-free (non-bacteriostatic) water for injection to each 20 mg vial of dantrolene; shake vials until solution is clear; give 2.5 mg/kg (1 mg/Lb) dantrolene IV rapid continuous push through a large bore IV line.",
"       </span>",
"       Example: for 72 kg patient, immediately reconstitute and administer 9 vials of dantrolene (20 mg each); watch for reversal of clinical signs (end-tidal CO2 should normalize); repeat as needed (up to 30 mg/kg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Get blood gas/labs",
"       </strong>",
"       : Venous gas (femoral) may be better than arterial gas to follow hypermetabolism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Give bicarbonate for acidosis",
"       </strong>",
"       : Sodium bicarbonate 1 to 2 mEq/kg IV push over 5 to 10 minutes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Cool the patient",
"       </strong>",
"       : Start when core temp &gt;39&deg;C; stop when core temp &lt;38&deg;C; cold saline for infusion; ice to body surface; lavage body cavities (eg, stomach, bladder, rectum)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       <strong>",
"        Treat hyperkalemia",
"       </strong>",
"       : Hyperventilate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Calcium chloride: Slow IV infusion over 2 to 3 minutes for life-threatening hyperkalemia; repeat after 5 minutes if ECG changes persist; adult: 0.5 to 1 gram (5 to 10 mL of 10% solution); pediatric: 10 to 20 mg/kg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Sodium bicarbonate: 1 to 2 mEq/kg IV push over 5 to 10 minutes; do not give sodium bicarbonate in the same line as calcium",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Insulin and dextrose: Monitor fingerstick glucose closely; adult: 10 units insulin IV push with 50 mL 50% dextrose; pediatric: 0.1 units insulin/kg IV push with 1 mL/kg 50% dextrose",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Treat dysrhythmias",
"       </strong>",
"       : Usually responds to treatment of acidosis and hyperkalemia; use standard ACLS protocols;",
"       <span class=\"red\">",
"        <strong>",
"         calcium channel blockers are contraindicated in the presence of dantrolene",
"        </strong>",
"       </span>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Ongoing care",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        <span class=\"red\">",
"         Continue dantrolene",
"        </span>",
"       </strong>",
"       : 1 mg/kg every 4 to 6 hours",
"       <strong>",
"        or",
"       </strong>",
"       0.25 mg/kg/hour as continuous infusion; maintain for at least 24 hours; further dosing may be indicated; (each 20 mg bottle of dantrolene contains 3 grams mannitol, protect dantrolene from light, once reconstituted stable for six hours)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Follow:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Urine output: Place Foley catheter; maintain at 1-2 cc/kg/hour; diurese if needed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Temperature: Maintain &lt;39&deg;C",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Blood gas: Normalize pH; optimize pCO2 and pO2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Electrolytes: Normalize",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Glucose: Check hourly and correct",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Creatine kinase: Check CK every 8 to 12 hours; alkalinize urine if CK &gt;10,000 IU/L",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Coagulation parameters: Watch for disseminated intravascular coagulation (DIC)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_50_24365=[""].join("\n");
var outline_f23_50_24365=null;
var title_f23_50_24366="Endarterectomy asymptomatic";
var content_f23_50_24366=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Carotid endarterectomy reduces stroke, but not endpoint of stroke and death, in asymptomatic men",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 439px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medical versus surgical (carotid endarterectomy) therapy in 444 men with asymptomatic carotid stenosis &ge;50 percent.",
"    <br>",
"     (Top panel) Carotid endarterectomy reduced the four year incidence of ipsilateral stroke or TIA compared to medical therapy (8 versus 20.6 percent, p&lt;0.001).",
"     <br>",
"      (Bottom panel) There was no difference between the two groups in the incidence of stroke and death (41 versus 44 percent) (lower panel).",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Data from: Hobson, RW, Weiss, DG, Fields, WS, et al, N Engl J Med 1993; 328:221.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_50_24366=[""].join("\n");
var outline_f23_50_24366=null;
var title_f23_50_24367="Fluoroscopy balloon dilat";
var content_f23_50_24367=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Creation of a cystgastrostomy for treatment of a pancreatic pseudocyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fluoroscopy view of guidewire exiting the curvilinear array echoendoscope and curling within the pseudocyst. The cystgastrostomy tract is being dilated with a balloon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Raj J Shah, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_50_24367=[""].join("\n");
var outline_f23_50_24367=null;
